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ABSTRACT 
 
This dissertation is in an integrated format discussing three major projects centered 
around probe development. In the first project, novel metal-chelated and fluorinated GLP-1 
derivatives were prepared all containing D-Ala-8, a modification known to improve 
resistance towards degradation by dipeptidyl-peptidase IV. The effect of increased distance 
between DOTA and the peptide chain was investigated using a spacer, in order to reduce 
steric effects imposed by DOTA. Placement of linker and DOTA moieties were varied within 
the GLP-1 sequence to test for optimal metal-complex location. Binding affinity of peptide 
derivatives was determined in vitro with CHO/GLP-1R cell line and shown to be in the nM 
range. In vivo imaging was carried out using C57BL/6 mice. Modifications made to the 
peptide backbone, based on charge distribution, were shown to improve pharmacokinetics. 
Our results suggest developed GLP-1 tracers to be potential candidates for the non-invasive 
imaging of pancreatic islets in vivo.   
In the second project, Gallium-chelated protoporphyrin IX (PPIX) derivatives 
containing the tripeptide RGD αvβ3-targeting moiety were prepared and evaluated. Reaction 
conditions for both naturally occurring 
69/71
Ga-labeling as well as 
68
Ga-radiolabeling were 
optimized using a microwave reactor. Optical properties were evaluated in order to study the 
effects of ligand conjugation and gallium chelation on absorption/emission properties of 
PPIX. Quantum yields pre- and post gallium chelation were comparable, indicating that the 
presence of gallium does not quench the inherent fluorescence of PPIX. The targeted 
compound was preferentially taken up by αvβ3 integrin-expressing cancer cells versus the 
non-targeted form, as assessed by fluorescence microscopy. Our results suggest that gallium-
iv 
 
 
PPIX conjugates could be used as dual modality positron emission tomography/fluorescence 
microscopy probes and can assist in bridging imaging agent discovery from in vitro 
microscopy through to in vivo imaging.  
In the third and final project, a novel high-throughput cell-based technique was 
developed for screening one-bead-one-compound (OBOC) libraries. In order to validate this 
technique, a small library consisting of heptameric peptides, and the αvβ3 integrins targeting 
RGD sequence, was synthesized on Tentagel beads via a photo-labile linker. Compounds 
were screened against the αvβ3-expressing MD 435 cell line. After fluorescent-based sorting, 
peptides were photolytically cleaved off resin and analyzed using MALDI-TOF/TOF. 
Deconvolution of all peptide sequences was carried out successfully indicating this screening 
process to be a facile and efficient technique for discovery of novel targeting entities.  
 
 
 
 
Keywords: Radiochemistry, Gallium-68, Indium-111, Fluorine-18, PPIX, GLP-1, OBOC 
library, molecular imaging  
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CHAPTER 1.    Molecular Imaging  
 
1.1       Introduction 
Over the past few decades, utilization of various imaging techniques has helped 
shape our understanding of numerous biological processes. Advances in the development 
of such techniques for small animals as well as human use, has increased the applications 
of imaging to include biomedical research, such as those in drug development and 
discovery. Historically, biomedical imaging methodologies relied on detection of disease 
processes or treatment effects as anatomical abnormalities and were therefore referred to 
as structural or conventional imaging. With the development of higher resolution 
instrumentation and discovery of improved imaging agents, it became possible to 
visualize physiological parameters in living subjects. This technique is commonly 
classified as functional imaging. More recently, however, it has become possible to 
image specific molecules and targets, which is a research discipline now referred to as 
molecular imaging.
1, 2
 This research area provides a method for the non-invasive 
visualization, characterization and quantification of biological processes at cellular and 
sub-cellular levels. Furthermore, molecular imaging has also been shown to play a vital 
role in modern medicine as a result of its potential application in diagnostics and 
therapeutics.
3-6
 Currently, two of the most important clinical applications of molecular 
imaging are in oncology and cardiac disease imaging. In oncology, significant 
breakthroughs have been achieved for treatment response assessment, cancer staging and 
early disease detection.
7-10
 In the case of cardiovascular disease, imaging techniques have 
provided a route for plaque detection as well as analysis of cardiac repair.
11, 12
 These 
applications were made possible largely due to the development of imaging probes.    
2 
  
1.2      Imaging Probes 
The non-invasive visualization of biological processes in vivo requires the use of 
appropriately designed imaging probes. There are three main categories of imaging 
probes namely: non-specific, targeted and activatable (Figure 1.1). Non-specific probes, 
instead of interacting with specific molecular targets, accentuate differences between 
tissues in terms of permeability and perfusion levels. These probes are typically utilized 
in monitoring disease processes, which involve characterization of blood volume, flow or 
perfusion. Non-specific probes are commonly utilized in imaging practices. A recent 
example is a report on tumor drug delivery by non-covalently linked drug-gold 
nanoparticle. In this study the gold-nanoparticles, acting as non-specific probes, travel to 
the tumor site via enhanced permeability and retention (EPR) effect owing to the 
presence of leaky vasculature as demonstrated in Figure 1.2.
2, 13-17
  
 
Figure 1.1 Representative classes of imaging probes and their respective interaction 
schemes.
14, 17
   
3 
  
 
Figure 1.2  A scheme demonstrating the localization of gold nanoparticles in tumors cells 
via enhanced diffusion through leaky vasculature.
13
  
 
 
Visualization and monitoring of disease processes requires targeting of specific 
biological processes at cellular or sub-cellular levels. This requirement has led to the 
development of targeted and activatable imaging probes. In principle, targeted probes get 
localized on biomolecules of interest, thus allowing for the visualization of their 
distribution.
14
 The mechanism of target-specific uptake is directly related to the 
biochemical processes involved since site directed probes could include enzyme 
substrates, inhibitors, transport protein ligands, membrane bound or cytosolic binding 
sites as well as mRNA or DNA components.
18
 Targeted probes are detectable at all times, 
regardless of any interaction with the biological target, which leads to higher background 
4 
  
noise levels. However, considering that only the probes bound to the biological targets 
stay in the system, higher signal to noise ratios can be obtained if waiting periods are 
permitted prior to imaging. Targeted probes are utilized in several areas of oncology 
including heart, brain and tumor imaging as well as tumor therapy. Examples of such 
probes and their applications are given in Table 1.1.   
 
Probe Structure Application 
FMISO 
 
Hypoxic marker for 
heart 
Carazolol 
 
α-Adrenergic receptor 
ligand (myocardial 
receptor present in many 
heart disease) 
Raclopride 
 
D2-dopamine receptor 
antagonist (dopamine 
activity in brain) 
  
Octreotide 
(Sandostatin®) 
 
Study somatostatin 
receptors found in a 
number of human 
tumors (eg. gastrinoma, 
insulinoma, carcinoid, 
neuroblastoma)  
FLT 
 
Monitoring tumor 
proliferation (eg. 
lymphoma) 
 
Table 1.1  Examples of targeted compounds for oncologic applications.
19-24
 
5 
  
Activatable probes (also referred to as smart probes), do not produce a signal in 
their native state and, considering that their detection requires interaction with their 
intended biological targets, typically produce higher signal to noise ratios. Smart probes 
can be activated by ionic interactions or enzymatic cleavage, and thus can also be used to 
monitor the localization of molecular functions. Figure 1.3 illustrates the use of 
activatable probes compared to other categories of molecular probes. A recently reported 
class of smart probes includes the pH-activatable fluorescent probes used in molecular 
imaging of viable cancer cells.
14, 25
 Pharmacokinetics of such probes, however, is not 
ideal in all cases, as interference from other biological entities (eg. enzymes) is likely to 
occur. Therefore, the choice of targeted versus smart probe is case dependent. 
 
 
 
Figure 1.3   Scheme of targeted imaging probes (a) versus activatable “smart” probes (b).     
6 
  
1.3   Design of molecular imaging probes 
The design of a molecular imaging probe requires special attention to a number of 
key factors, the most important of which are 1) identification of a suitable biological 
molecular target, 2) identification of a targeting entity with optimal affinity for the target 
of interest, 3) labeling of the targeting entity with a suitable signaling molecule, thus the 
modality, 4) overcoming the barriers in the biological delivery of the designed probe, and 
5) if possible, finding ways to amplify the observed probe signal.
14
 Figure 1.4 illustrates 
the general design of a targeted molecular imaging probe.
14
     
    
 
 
  
Figure 1.4  Components of an imaging probe and its interaction with a biological target.  
 
Finding the appropriate targeting ligand requires a screening process. Such 
techniques are currently employed in the drug development industry and include phage 
display, proteomics, robotics, recombinant techniques, and high throughput screening 
methods, which have only recently been widely employed to identify molecular imaging 
targets. Examples of potential molecular targets include nucleic acid sequences, proteins, 
carbohydrates and lipids (Figure 1.5). The design of imaging probes requires several 
considerations, which include: probe localization on the cell surface or within the cell, 
quantity of biological target per cell, and probable steric issues that may hinder probe 
delivery.
14, 17
  
7 
  
 
Figure 1.5   General outline of a cell showing commonly targeted entities.  
 
The next step in the design of an imaging probe, once a biological target has been 
selected, is the identification of a molecule that would specifically bind the target with 
optimal affinity. The targeting entity can range in size from a small molecule (eg. 
receptor ligand), to a larger molecule such as a monoclonal antibody. The identification 
of this entity is usually performed using library based screening, phage display or in 
silico (ligand screening).
14, 26
 Depending on the properties of the molecule and the 
modality of choice, a signaling ligand is then bound to the selected targeting entity. For 
nuclear imaging, radioisotope labeling, typically carried out by chelation or covalent 
coupling reactions, is required.
27
 Optical imaging on the other hand, requires organic 
fluorophores or inorganic compounds, such as quantum dots, for fluorescence imaging, or 
naturally occurring substrates for bioluminescence optical imaging.
28
  
The designed imaging probe should also possess the appropriate characteristics in 
order to bypass all biological barriers (Figure 1.6) and reach the target of interest, within 
a reasonable time period, in sufficient concentration. The most important properties of the 
8 
  
developed probe in vivo are absorption, distribution, metabolism, and elimination 
(pharmacokinetics). In order to leave the vascular system, the vascular walls would need 
to be traversed. Lower molecular weight imaging probes can extravasate and be 
distributed in both target and non-target tissues, thus decreasing signal to noise ratios. 
Extravasation, however, is not always feasible. While tumors or inflammatory tissues 
with leaky vasculature are easier to traverse, traversing the blood brain barrier tends to be 
less permissible. Once the probe crosses over into the targeted tissue, it would have to 
overcome other barriers, such as steric issues preventing proper probe delivery, in order 
to reach the targeted cell.
14, 17, 29, 30
  
 
 
Figure 1.6   Examples of biological barriers that could prevent proper delivery of an 
imaging probe.
2, 14, 17
  
 
1.4   Targeting Component  
As discussed earlier, the targeting entity can range in size from a small molecule 
(eg. receptor ligand), to a much larger molecule such as an antibody. The work presented 
in this dissertation concerns the use of peptide-based compounds as the targeting 
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component for the development of molecular imaging probes. The use of peptide 
derivatives and their applications are discussed in detail below.    
Receptor targets used for peptide-based radiopharmaceuticals are most commonly 
among the family of seven transmembrane proteins, often referred to as G-protein-
coupled receptors (GPCRs). This family contains the largest class of human receptors of 
pharmacological importance, consisting of approximately 50% of reported clinically 
relevant drugs acting on its protein members. Advances in proteomics and genomics have 
led to the discovery of several hundred GPCRs, some of which have been reported to 
have peptide-based endogenous ligands. Some of the most promising examples of 
peptide-based drugs and imaging agents are directed towards the somatostatin and 
bombesin receptor family. Peptides have been extensively utilized as drug candidates in 
two basic categories namely peptides directed towards tumor cell-surface receptors 
(Table 1.2) and those targeted towards tumor vasculature.
31-44
  
 
Peptide GPCR Cancer targets 
Bombesin / gastrin 
releasing peptide 
GRP-R (BB2) Prostate 
Cholecystokinin CCK2-R Medullary thyroid 
GLP-1 GLP-1R Insulinomas 
Neurotensin  NTR1 Pancreatic cancer 
Somatostatin SST2 (most common) Neuroendocrine tumors 
Neuropeptide Y NPY1 Breast 
Substance P NK1R Glioblastoma 
 
Table 1.2  Examples of peptides targeting GPCRs. 
 
Tumor vasculature targeting is employed in monitoring processes involved in 
tumor growth. Tumor cell proliferation requires enhanced blood supply, making 
angiogenesis a necessity in tumor growth beyond 1-2 mm. Enhanced angiogenesis is 
10 
  
accompanied by over-expression of many biological factors such as integrins, growth 
factors and proteases. As a result, a large number of peptide-based imaging probes have 
been developed to monitor the over-expression of these biological factors during the 
progression of angiogenesis.
45, 46
 Examples include peptides containing the αvβ3-integrin 
targeting moiety Arg-Gly-Asp.
47
  
As targeting agents, peptides provide a number of advantages over other 
molecules, which is particularly accentuated when considering their synthetic route and 
diversity. Synthesis of peptides using automated solid-phase methodologies allows for 
rapid production of analogues in a reasonable time frame. The commercial availability of 
unnatural amino acids, further extends the chemical diversity of peptides prepared by this 
methodology. Furthermore, peptide-based probes have shown to have lower antigenicity, 
rapid access to tumors, enhanced tumor penetration, as well as faster clearance rates.
31
  
Major drawbacks associated with using peptide-based compounds include poor 
oral bioavailability and poor metabolic stability. Fortunately, the former is not a major 
concern in oncology as most radiopharmaceuticals are administered intravenously. In 
addition, the metabolic stability of peptides in vivo has shown to improve using a variety 
of structural modifications known to prevent enzymatic degradation. The design of 
suitable and robust peptide-based probes therefore needs to account for the following 
considerations: biological stability, target affinity, target specificity, and pharmacokinetic 
characteristics. Steps in this methodology include design, synthesis and biological 
evaluation of the best peptide candidates. Initial biological evaluation analysis could 
consist of competitive binding assays or cell-based assays, with a focus to create probes 
with high affinity and specificity for the desired protein target. Additional studies will 
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then aid in creating a molecule exhibiting biological stability. While results obtained 
from in vitro analyses do not necessarily reflect those from in vivo studies, they are 
certainly a reasonable starting point in screening for successful candidates. In the next 
stage, the pharmacokinetics of developed peptide candidates are evaluated in vivo.
31
             
 
1.5      Labeling Techniques 
1.5.1   Fluorophore Labeling 
Fluorescent dyes are commonly conjugated onto biological compounds using 
either coupling reactions (eg. amine and an activated carboxylic acid), or direct 
nucleophilic reactions between a reactive group (eg. amine, thiol, alcohol) and a 
fluorophore. One of the most utilized groups, especially in peptide chemistry, are amines 
which are reasonably nucleophilic above pH 8.0 and can be reacted with activated 
fluorophore esters, such as N-hydroxysuccinimide (NHS) ester, with high yields and 
reproducibility.
48
 Activated esters, such as the NHS esters, typically exhibit high 
selectivity towards aliphatic amines, while having low reaction rates with aromatic 
amines, alcohols and phenol. Fluorophore conjugation to amines can also be carried out 
using isothiocyanates, which are routinely employed in conjugation of fluorescein 
derivatives. In the absence of a reactive amine, thiols could also be utilized in such 
reactions. This is achieved via maleimide-thiol reaction at pH 7. Handling of thiol-
containing compounds, however, is more tedious in the presence of multiple thiols, which 
could lead to the formation of disulfide bridges. In these situations, addition of a reducing 
agent such as dithiothreitol (DTT) is required.
49
 Table 1.3 lists examples of commercially 
available dyes used for conjugation of fluorescein.
50-54
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Compound Structure 
Fluorescein  
 
 
6-[Fluorescein-5(6)-
carboxamido]hexanoic acid N-
hydroxysuccinimide ester 
 
 
 
 
Fluorescein 5(6)-isothiocyanate 
 
 
 
 
N-(5-Fluoresceinyl)maleimide 
 
 
 
 
 
Table 1.3  Examples of commercially available fluorescein derivatives directed towards 
reactions with amines and thiols.  
 
1.5.2   Radionuclide labeling 
Radioisotope labeling reactions can be organized into six general categories, 
which are isotope exchange, recoil labeling, excitation labeling, biosynthesis, direct, and 
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bifunctional chelator/prosthetic group labeling. In radioisotope exchange reactions, one 
or more atoms in a molecule are replaced by their radioactive counterparts. Considering 
that these molecules (pre and post labeling) are identical, with the only exception being 
an isotope effect, it is expected that they would possess the same biological and chemical 
properties. Examples of radiolabeled compounds produced by isotope exchange are 
125
I-
triiodothyronine, and 
125
I-thyroxine.
55
        
Recoil, excitation and biosynthesis labeling methods are not within the scope of 
this work. However, in brief, recoil labeling utilizes recoil atoms, produced in a nuclear 
reaction, to generate radiolabeled compounds. Unfortunately, the high energy of these 
particles results in poor yields and low specific activity. An example of such a reaction is 
6Li(n,α)3H, where the compound to be labeled is mixed in with a lithium salt and 
subsequently irradiated in the nuclear reactor. Similarly, excitation labeling entails the 
utilization of radioactive daughter ions in a nuclear decay process to label compounds of 
interest. An example is the decay of 
77
Kr to 
77
Br. In this reaction, exposure of the 
compound of interest to 
77
Kr results in labeling with 
77
Br. Biosynthesis is a process where 
a living organism is grown in a culture medium containing the radioisotope of interest. In 
this methodology, the tracer is incorporated into the metabolites produced by the 
metabolic process of the organism and is subsequently separated. Examples of this 
process include 
60
Co and 
57
Co-labeled vitamin B12.
55
 
Direct labeling methods entail the attachment of a radionuclide to the molecule of 
interest without the need for a prosthetic group. An example of such procedure includes 
the binding of radionuclides to thiol groups in the targeting molecule. This methodology, 
although easy to perform, is difficult to control and may lead to undesired changes in the 
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structure, stability, and pharmacokinetics of the labeled molecule.
56, 57
 The 
characterization of compounds produced from this methodology is also extremely 
difficult owing to the lack of a complete understanding of the number of donor atoms and 
the possible geometry of the incorporated radionuclides.
55
 A more precise approach, 
perhaps, is radiofluorination which is carried out via nucleophilic or electrophilic 
routes.
58
 
The last methodology, which is now the most utilized, is an indirect radiolabeling 
approach, where a prosthetic group or a radiometal chelator containing the radionuclide, 
is conjugated onto the biological compound of interest. This methodology, most widely 
employed in radiolabeling of peptides and proteins, takes advantage of reactive functional 
groups naturally present in these compounds for covalent attachment of the radionuclide 
containing moiety. Once again, several types of conjugation groups can be used such as 
active esters, isothiocyanates, maleimides, hydrazides, and α-haloamides (Figure 1.7). 
The choice of the conjugation group is widely dependent on the reactivity and ease of 
product isolation. For instance, water soluble NHS-esters could be used for conjugation 
reactions to water insoluble peptides, in order to facilitate their removal. In the opposing 
case, the ether-soluble p-nitrophenyl esters could be used for water soluble peptides.
59-61
  
Bifunctional chelator/prosthetic group methodology can be carried out using pre-
labeling or post–labeling approaches. In the first approach, the radiolabeling of the 
prosthetic group/chelator is carried out initially, which is then followed by covalent 
conjugation of this entity to the biological molecule of interest. As the labeling and 
conjugation steps are separated, this procedure ensures the proper attachment of the 
radionuclide to the chelate moiety. However, the pre-labeling process could interfere with 
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the conjugation process, thus further complicating the required purification steps. This 
process is also extremely time consuming and laborious and may not be optimal for 
short-lived radioisotope labeling. As a result, this approach is less commonly employed 
in radiolabeling procedures.
59, 62, 63
  
In contrast, the post-labeling methodology, being most popular, requires the 
synthesis of a conjugate that is ready for radiolabeling (eg. metal-chelator peptide 
complex). This approach typically results in high yields and is compatible with solid-
phase or solution phase chemistry. However, harsh conditions are required for effective 
labeling of conjugates, which could result in decomposition of starting materials.
59
 A 
group of widely utilized bifunctional chelators are radiometal chelators, which have 
recently gained much interest. Examples of some well known chelators include DTPA, 
DOTA, TETA, and NOTA (Table 1.4).
59
   
Bifunctional metal chelators are used to connect a radiometal to a targeting 
moiety. Metal-chelator complexes have been reported to be very stable both in vitro and 
in vivo. Many variations of caged metal chelators have also been reported in order to 
further enhance their respective biological stability. An ideal chelator is expected to 
coordinate the radionuclide with ease, great stability, and in high yields. The chelator 
must also be compatible with the radiometal of choice as it should not result in changes in 
oxidation states or redox potentials. DTPA, has been shown to be a strong chelating agent 
for trivalent metals such as indium-111.                      
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Figure 1.7    Examples of reactive group chemistry for conjugation of a prosthetic group 
or bifunctional chelator, X; (a) activated ester, (b) isothiocyanate, (c) 
maleimide, (d) hydrazide, (e) α-haloamide.59   
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Chelator Structure 
DTPA  
 
 
DOTA  
 
 
TETA  
 
 
NOTA  
 
 
 
Table 1.4    Examples of radiometal chelators commonly used with Indium-111 and 
Gallium-68.  
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There have been reports of DTPA conjugation to larger proteins (eg. albumins 
and antibodies), as well as smaller peptides such as somatostatin analogues.
64-66
 The 
cyclen derivatives 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetracetic acid 
(DOTA),
67-71
 1,4,7-triazacyclononae-1,4,7-triacetic acid (NOTA),
72, 73
  and their 
analogues, have played an important role in clinical applications as they form very stable 
complexes with a variety of trivalent radiometals such as 
66,67,68
Ga, 
86,90
Y, 
111
In, 
149
Pm, 
177
Lu, as well as the divalent radiometals 
27
Mg, 
47
Ca, and 
64
Cu. TETA (1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid), is one of the most well studied 
chelating agents for copper in peptide-based targeted radiotherapy (eg. somatostatin 
analogues).
59, 74, 75
           
 
1.5.3   Important Considerations in Radiolabeling  
Several factors need to be considered when preparing radiolabeled compounds. A 
high radiochemical yield is always desired, especially in cases utilizing short-lived 
radioisotopes. The employed radiolabeling approach should result in the formation of the 
most chemically stable conjugate, as the stability of the tracer is first and foremost 
determined by that of the radionuclide-conjugated entity. Optimization of labeling 
reaction conditions (eg. pH, temperature) is a necessity in order to prevent decomposition 
of the targeting entity. These conditions, to some extent, also dictate the most accessible 
approach for radiolabeling. Radiochemicals could be adsorbed on the inner walls of 
containers if they are in a carrier-free environment. In this case, low radiochemical yields 
can be avoided by using either silylated containers or those made of quartz. Storage 
conditions for the materials would also have to be determined based on the half-life of the 
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radioisotope and the overall stability of the compound. Another important variable is 
specific activity (the number of decays per amount of product), which is a measure of the 
ratio between radiolabeled and non-labeled compounds present in the final product (eg. 
non-radiolabeled starting materials). As a result, precautions should be taken to ensure 
optimal specific activity products. This value, however, is not always required to be high 
since, in certain cases, high levels could lead to product radiolysis (decomposition by 
radiation). Separation techniques would also have to be developed for the isolation and 
purification of the final labeled compounds as radioactive contaminants are often formed 
as byproducts of radioisotope decay.
55
  
The choice of radionuclide is also important and requires consideration in 
determining the proper conjugating moiety. Important factors to consider are the half-life 
of the isotope, its mode of decay and availability. For diagnostic imaging, the half-life 
should be long enough to allow for the synthesis and purification of the desired probe, 
while still allowing for the administration of the tracer, its accumulation in the target 
tissues, and its clearance through non-targeted organs. At the same time, however, the 
half-life of the selected radioisotope should be as short as possible in order to prevent 
unnecessary radiation exposure.
59
            
 
1.6   Imaging Modalities 
 The most routinely used imaging techniques are nuclear, magnetic resonance, 
and optical, which are again categorized according to the type of signaling molecule 
used.
1, 2, 76
 For instance, nuclear techniques use radioactive isotopes, while magnetic 
resonance and optical techniques utilize paramagnetic particles and fluorescent tags as 
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the signaling entity, respectively. The choice of the signaling entity, and therefore the 
modality, is dependent on the target of interest as it determines the most important 
imaging variables, such as sensitivity or resolution (Figure 1.8). The work presented in 
this thesis focuses on nuclear and optical techniques, which are discussed in more detail 
below.  
 
 
 
Figure 1.8   Examples of available in vivo imaging modalities for small animal 
imaging.       
 
1.6.1   Nuclear Imaging 
Nuclear imaging, or more specifically emission tomography, involves the use of 
radioactive isotopes as signaling entities. Two of the most commonly used modalities in 
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radionuclide imaging are positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT). In both instances, a small quantity (pM) of a 
radiopharmaceutical is introduced into the body in order to non-invasively monitor the 
physiological functions of interest. The visualization of the radiopharmaceutical is made 
possible by detection of gamma rays that are emitted from the radionuclide.
2
 
 
1.6.2   PET 
Radioisotopes that are used in PET decay by way of positron emission. The 
emitted positrons then travel a short distance through the body until they come in contact 
with electrons. The resulting electron-positron annihilation reaction then leads to the 
formation of a pair of anti-parallel 511 keV photons, which are simultaneously detected 
by a set of adjacent detectors. The lines outlining the traveled path of photons, and 
intersecting adjacent detectors, is referred to as the line of response (LOR). The 
cumulative LOR’s are then used to reconstruct the 3D distribution of the positron-
emitting radiopharmaceutical within the patient (Figure 1.9).
77, 78
    
The sensitivity of PET is in the pM range and is independent of the location and 
depth of the probe. Typically, several million cells containing the tracer are required for 
proper detection and recording of the event by the PET scanner. The high sensitivity of 
PET renders this imaging technique valuable for in vivo visualization of biological 
processes. It is worth noting, however, that because all emitted gamma rays in PET 
posses the same energy, if two imaging probes containing different radioisotopes were to 
be simultaneously injected, it would not be possible for PET detectors to distinguish 
them. As a result, imaging tracers have to be administered and processed individually. 
22 
  
 
 
Figure 1.9   Mechanism of photon detection in PET. 
 
 
As a result of the versatility of PET, there has been a tremendous increase in the 
number of PET radiotracers and clinical applications. The most frequently utilized PET 
radioisotopes are 
18
F, 
82
Rb, 
11
C, 
15
O, and 
13
N, (Table 1.5) while the most notable PET 
radiotracer is 
18
F-FDG (Figure 1.10).
79
 Considered the golden standard in PET imaging, 
18
F-FDG is used in the evaluation of several neoplasms and radiotherapy planning in 
various cancers such as those in lung, head and neck. A large number of other 
radiotracers are also currently being used in oncologic PET imaging. Some examples of 
such probes are listed in Table 1.6.
77, 78
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Figure 1.10  Structure of 
18
F-FDG. 
 
 
 
  Radioisotope Half-life Modality 
Rubidium-82 1.25 min PET 
Oxygen-15 124 sec PET 
Nitrogen-13 9.96 min PET 
Carbon-11 20.4 min PET 
Fluorine-18 110 min PET 
Technetium-99m 6.02 hours SPECT 
Iodine-123 13.2 hours SPECT 
Indium-111 2.83 days SPECT 
Gallium-67 3.26 days SPECT 
Iodine-131 8.02 days SPECT 
 
Table 1.5  Common radioisotopes used in PET/SPECT imaging. 
 
 
 
 
(a) 
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Tracer Measured Variables 
11
C/
18
F-thymidine  DNA synthesis 
11
C-methionine  Protein synthesis 
11
C/
18
F-choline Cell-membrane metabolism  
11
C/
18
F/tyrosine, ethyltyrosine  Natural amino acid transport 
18
F-fluoro-
dihydroxyphenylalanine 
Dopamine synthesis, natural 
amino acid transport  
18
F-fluoro-misonidazole Tissue hypoxia 
18
F-fluoro-17-β-estradiol Estrogen-receptor status 
18
F-fluorouracil  Tumor uptake of 5-fluoro-uracil 
11
C-acetate Lipid synthesis 
 
Table 1.6  Examples of PET tracers used in oncology.
77, 79-88
  
 
1.6.3   SPECT 
PET and SPECT are generally distinguished by the type of radioisotope employed 
in their respective imaging probes. While PET makes use of positron emitting 
radioisotopes, which lead to the formation of two anti-parallel photons of equal energy, 
SPECT employs radioisotopes which emit only a single gamma-ray photon with each 
radioactive decay. This distinction between the numbers of emitted photons determines 
the type of hardware and software used to detect localized radiopharmaceuticals.
77
  
SPECT imaging techniques, much like PET, start with the administration of a 
radiopharmaceutical. Following the decay of the administered radioisotope, gamma rays 
are collected by a collimator. This component is typically a thick sheet of a heavy metal, 
such as lead, that is shaped like a honeycomb with long thin channels. The collimator 
collects gamma rays that travel in the specific direction of the honeycomb channels, and 
directs them towards a crystalline material called a scintillator. The scintillator uses the 
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energy from the detected gamma rays to produce many optical wavelength photons, 
which are detected and converted to a cascade of electrons by a collection of 
photomultiplier tubes. The produced current is then acquired by accompanying 
electronics which record the occurrence of this event. Registration of multiple events then 
leads to the projected image of the object (Figure 1.11). Common radioisotopes used for 
SPECT imaging are 
99m
Tc, 
111
In, 
123
I, and 
131
I (Table 1.5).
77
  
Compared to PET, SPECT uses lower energy γ rays, while providing the same 
spatial resolution (1-2 mm). Utilization of SPECT also allows for simultaneous detection 
of multiple isotopes with varying γ energies. A drawback of SPECT, however, when 
compared to PET, is its reduced sensitivity (10
-10
-10
-11 
M
 
for SPECT compared to         
10
-11
-10
-12
 M for PET).
2, 77
 Clinical applications of SPECT are numerous some of which 
have been listed in Table 1.7. 
 
 
 
Figure 1.11    Schematic diagram of a conventional gamma camera setup used in SPECT 
imaging.
77 
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Radiopharmaceutical  Application 
67
Ga-citrate Infection or lymphoma detection 
111
In-capromab pendetide Prostate cancer detection 
201
Tl-TlCl Myocardial perfusion or viability 
assessment  
99m
Tc-sestamibi or tetrofosmin Myocardial perfusion or viability 
assessment, Parathyroid 
localization 
99m
Tc-MDP Metastases or fracture detection 
99m
Tc-Red blood cells Liver hemangioma detection 
99m
Tc-sulfur colloids Liver/spleen assessment, 
lymphoscintigraphy 
99m
Tc-HMPAO Brain perfusion assessment 
 
 
Table 1.7    Clinical applications of radiopharmaceuticals used for SPECT imaging; 
HMPAO = hexamethylpropyleneamine-oxine; MDP = methylene 
diphosphonate.
89-97
   
 
 
1.7   Radioisotope production 
Radioisotopes, in general, can be categorized as being neutron rich or neutron 
poor. Isotopes that are neutron rich are produced in a reactor, whereas those that are 
electron poor are produced in particle accelerators. The use of the latter, and in particular 
cyclotrons, is preferred over the use of reactors. This is due to several reasons which are: 
1) unfavorable decay characteristics of reactor produced radioisotopes, such as particle 
emissions and gamma ray energies, for certain applications, 2) reactor produced 
radioisotopes cannot be produced with high specific activities, and most importantly 3) 
access to reactors is more limited when compared to cyclotrons.
98
 As a result, the 
radioisotopes used in this thesis were all produced, either directly or indirectly, by 
cyclotron accelerators.  
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1.7.1   Cyclotrons 
There are currently a large number of nuclear reactions that can be used in 
accelerators to produce radioactive materials. The bombarding particles are usually 
protons, deuterons, or helium particles. The energies used range from a few MeV to 
hundreds of MeV. In a typical reaction, the accelerated particle, along with its energy, are 
absorbed into the nucleus of the target materials. This energy distribution in the nucleus 
become homogenous (equilibrates), prior to decomposition and particle emission, thus 
leading to the formation of the desired radioisotope. Figure 1.12 shows the setup of a 
cyclotron.
98
     
A particle accelerator is surrounded by both inner and outer shields (Figure     
1.12 a). The inner shield is approximately 30 cm thick consisting of a mixture of lead, 
epoxy, and boron carbide, whereas the outer shield is roughly 70 cm thick and consists of 
polyethylene and boron carbide loaded concrete. The cyclotron core, which is always 
under high vacuum, consists of two D-shaped electrodes (Figure 1.12 b), to which 
alternating voltage is applied. With the aid of an electromagnetic field perpendicular to 
the electrodes, charged particles are accelerated in an outward spiral path within the 
hollow Ds in the high vacuum environment (Figure 1.12 c). These particles, produced at 
the source, can be either positively (eg. H
+
) or negatively (eg. H
-
) charged ions. In a 
proton cyclotron, hydrogen gas, which is directed into the cyclotron chamber, gets 
ionized by electrons emitted from a cathode. This results in the formation of both 
positively and negatively charged protons, which are separated based on the type of 
cyclotron and the direction of the magnetic field. The energy of the accelerated particles 
can reach several MeV depending on the size and design of the cyclotron. After 
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acceleration, these particles are then brought in contact with the target materials, causing 
the formation of the desired radioisotopes.
78, 99
 Three cyclotron produced radioisotopes 
that will be further discussed in this thesis are listed in Table 1.8. 
 
 
 
 
 
 
 
 
Figure 1.12  A cyclotron setup with protective shields (a) closed and (b) open; courtesy 
of Hamilton Health Sciences; (c) demonstrates components of the cyclotron 
core.
100
  
(a) (b) 
(c) 
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Radionuclide Nuclear 
Reaction 
Half life 
Fluorine-18 
18
O(p,n)
18
F 109.8 min 
Indium-111 
111
Cd(p,n)
111
In 2.8 days 
Germanium-68 
69
Ga(p,2n)
68
Ge* 272 days 
            
Table 1.8   Cyclotron produced radionuclides discussed in this work; *denotes the use of 
isotopically enriched materials.
98
   
            
Among the available radionuclides, the use of short-lived radioisotopes has 
gained considerable interest, which is due to the added capability of administering larger 
radiopharmaceutical dosages into patients while minimizing their received radiation dose. 
This methodology also results in the production of high quality images. The increasing 
interest in short-lived isotopes has resulted in the development of radionuclide generators 
that serve as convenient sources for their production.
98, 101
 
 
1.7.2   Radionuclide Generators      
Generators are constructed based on the decay-growth relationship between a 
long-lived radionuclide and its shorter-lived daughter radionuclide. A long-lived 
radioisotope is allowed to decay to its short-lived daughter. Distinct differences in the 
chemical properties of the two nuclides are then utilized for the isolation of the daughter 
nuclide from the parent. Generators consist of a glass or plastic column fitted at the 
bottom with a fritted disk. The parent nuclide is then adsorbed onto the column packing 
which could be made of various materials such as cation/anion exchange resin, alumina 
or zirconia. Decay of the parent nuclide, and the subsequent formation of its daughter, 
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continues until an equilibrium is reached within several half-lives of the daughter nuclide. 
Once an equilibrium is reached, the half-life of the daughter would appear to be the same 
as that of its parent. The elution of the generator would bring out the daughter while 
leaving the parent nuclide adsorbed on the column. After an elution, the daughter nuclide 
starts to form again in the generator until an equilibrium is reached, as mentioned above, 
at which point another elution can be carried out. Figure 1.13 illustrates the outline of a 
radionuclide generator.
55
       
 
 
 
Figure 1.13  Illustration of a radionuclide generator set-up.  
 
Generators, while simple and convenient to use, provide high yields of the 
daughter nuclide reproducibly and are shielded to minimize radiation exposure. The 
shipment of generators is facile since they are sturdy and compact, making them ideal 
Reaction 
Vessel
Eluent
Lead 
Shield
Column 
+ 
adsorbed 
parent 
radionuclide
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candidates for both research and medicinal applications. Table 1.9 provides a list of 
generators employed in nuclear medicine.      
 
1.7.3   Optical Imaging 
Optical imaging techniques, much like radionuclide imaging, are varied based on 
the modality of choice. Traditionally, optical methods were used for surface and 
subsurface fluorescence imaging using confocal imaging, multiphoton imaging, 
 
Parent Parent 
t1/2 
Daughter Daughter 
t1/2 
Column  
Packing 
Eluant 
99
Mo 66 h 
99m
Tc 6 h Al2O3 0.9% NaCl 
113
Sn 115 d 
113m
In 99.5 min ZrO2 0.05 N HCl 
68
Ge 271 d 
68
Ga 68 min Al2O3; SnO2  0.005 M EDTA; 1 N 
HCl 
62
Zn 9.3 h 
62
Cu 9.7 min Dowex 1 x 8 2 N HCl 
137
Cs 30 y 
137m
Ba 2.6 min Ammonium 
molybdophosphate 
0.1 N HCl + 0.1 N 
NH4Cl 
81
Rb 4.6 h 
81m
Kr 13 s BioRad AG 50 H2O 
82
Sr 25.5 d 
82
Rb 75 s SnO2 0.9% NaCl 
191
Os 15.4 d 
191m
Ir 4.9 s BioRad AG1 4% NaCl 
195
Hg 41.5 h 
195m
Au 30.6 s Silica gel coated 
with ZnS 
Na2S2O3·5H2O 
solution 
87
Y 80 h 
87m
Sr 2.8 h Dowex 1 x 8 0.15 M NaHCO3 
 
Table 1.9  Examples and specifications of generators used in nuclear medicine.
102
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microscopic imaging by intravital microscopy, or total internal reflection fluorescence 
microscopy. More recently, however, imaging of deeper tissues has become possible with 
the aid of continuous light or with intensity-modulated light and tomographic systems.
103
 
This development has also been largely due to the discovery of near infrared probes that 
exhibit deeper tissue penetration, which results from lower tissue light absorption at 
longer wavelengths.
104
  Given all the recent improvements in probe and instrumentation 
development, the penetration depth for near infrared dyes is expected to reach up to 
several centimeters. However, given the poor depth penetration, optical techniques are 
still largely limited to small animal imaging as there are currently few clinical 
opportunities.
2
 
Optical imaging techniques have been utilized to study gene expression, cell 
trafficking, and drug efficacy. Two techniques utilized in this area are fluorescence 
imaging (FI) and bioluminescence imaging (BI), both of which provide a cost-effective 
methods for high-throughput screening of biological targets and functions in small animal 
models such as mice. Advantages of optical imaging include its high sensitivity, ranging 
10
-9
 to 10
-12
 M (optical fluorescence imaging), probe stability as there is no radioactive 
decay, and its non-ionizing nature. Equally important is the capability to follow multiple 
optical probes, labeled with dyes with varying fluorescence wavelengths, in the same 
study.
2, 105
 The particular technique used in this thesis was fluorescence imaging which is 
discussed more in detail.     
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1.7.4   Fluorescence Imaging 
In FI, an excitation light source of a specified wavelength is used to excite a 
fluorophore. The subsequent relaxation of energetically promoted electrons then results 
in the emission of longer wavelength photons which are recorded by a detector. 
Fluorescent probes exhibit great sensitivity due to this discrete emission of light upon 
excitation, leading to a number of applications such as those involving in vitro assay 
procedures (eg. fluorescently tagged antibodies for antigen detection). In general, each 
fluorophore exhibits unique optical properties such as signal intensity, 
excitation/emission wavelengths, as well as quantum yields (ratio of total photon 
emission, over the entire range of fluorescence, to the total photon absorption), and 
extinction coefficients. These properties are key components in the design of optical 
imaging probes as they determine the type of instrumentation required. A fluorescent 
compound is expected to not only possess a high quantum yield, but to also exhibit a 
large Stoke’s shift (difference in absorption and emission wavelengths). Greater Stoke’s 
shifts minimize interferences from Rayleigh-scattered excitation light, thus resulting in 
higher signal to noise ratios. Another important fact to keep in mind when selecting the 
appropriate fluorophore, is the naturally occurring background fluorescence of the 
surrounding tissues, which could result in the reduction of signal to noise ratios.  
Perhaps the most widely used fluorophore is the green fluorescent protein (GFP) 
which is often used in in vitro studies such as assays for reporter genes. Other common 
classes of fluorescent tags include the fluoresceins, rhodamines, coumarins, BODIPY, 
cascade blue, Lucifer yellow, phycobiliproteins and cyanine dyes. Table 1.10 lists 
examples of applications of optical imaging.  
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Probe Application 
Peptide-based NIR 
activatable optical probes 
Cancer imaging, thrombosis, atherosclerosis, 
apoptosis, arthritis  
Luciferase, GFP Imaging gene expression 
 
Table 1.10  Examples of optical imaging applications in living subjects.
106-112
 
 
 
1.8  Imaging Probe Design:  Overall Picture 
Combination of a targeting moiety, signaling component and imaging modality 
for analysis of a particular biological target encompasses the design of an imaging agent. 
Over the years, a large number of probes have been reported for use by various imaging 
modalities as mentioned above. However, it is not uncommon for a number of probes to 
have the same biological target. This is due to the options created from the combination 
of targeting moiety, signaling component and imaging modality. As a result, in order to 
circumvent this overlap, multimodality imaging was developed for the production of 
single molecules that could be used with various modalities, thus maximizing the amount 
of data obtained with a single tracer.          
 
1.9   Multimodality Imaging  
In recent years, the use of multiple modalities in conjunction has gained 
considerable interest. These techniques combine individual strengths of modalities, thus 
leading to more accurate imaging results and experiments. The first fused system was a 
PET/CT instrument, which was developed by Townsend and colleagues, in collaboration 
35 
  
with Siemens Medical, in 1998.
113
 The success of this invention led not only to the 
development of other fused systems, but also extensive research in the design of novel 
multimodality imaging agents. In the development of multimodality imaging probes, 
while not necessitated by all application, use of a single probe for multiple modalities can 
aid in maintaining consistent pharmacokinetics and co-localization properties.
113
 This 
would also prevent any additional unnecessary stress on the body, which would 
accompany multiple probe administration. Keeping this in mind, over the past two 
decades, various types of multimodality imaging agents have been reported with 
structures based on lipids (eg. liposomes and lipoproteins),
114, 115
 nanoparticles (eg. 
quantum dots,
116
 iron-oxide particles,
117
 dendrimers
118
), macromolecules (eg. 
peptides),
119
 and small molecules.
113, 120
 Of these categories small molecules and 
dendrons are commonly used in the development of single and multimodality molecular 
imaging probes. These categories are discussed in more details below.  
 
 
1.9.1   Dendrimers 
Dendrimers are an assembly of branched polymers that terminate in numerous 
functional groups (eg. hydroxyl or amine groups), which can be further utilized for ligand 
conjugation. The more suited biocompatibility of dendrimeric compounds (when 
compared to peptides, quantum dots and some small molecules), has resulted in their 
increasing utilization in medicinal chemistry.
121
 Two of the most utilized applications 
include drug delivery (eg. cyclodextrins),
122
 and gene delivery (eg. lysine-
polyethyleneglycol-lysine dendrimers).
123,124
 Peptide-dendrimers have shown to be 
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potential candidates as protein mimics, anticancer agents and vaccines. Peptide-
dendrimers are typically more water soluble, less toxic to normal human cells, and more 
stable to proteolysis when compared to their linear analogues. Dendrimeric structures 
have also been frequently used in molecular imaging.
125
                 
Dendrimers with various tags have already been reported including metal-chelator 
complexes (eg. Gd-DTPA),
118, 126, 127
 and fluorescent tags (eg. rhodamine,
128
 Alexa 
Fluor,
142
 and Cy5.5
129
). The branched chains, typically consisting of polyamidoamines 
(PAMAM), provide a large number of functional groups on the surface, while 
minimizing the overall size of the nanoparticle. For instance, the size of a third generation 
(being the number of repeated branched cycles) dendrimer (G3) is approximately 4 nm 
while that of a G8 dendrimer is roughly 10 nm. The control over the size of these 
particles is very important in determining the pharmacokinetic behavior of the probe in 
vivo. For example, the clearance of dendrimers is by the renal system for G3-4 
dendrimers, kidney and liver for G5 dendrimers, and only via liver for G6-9 dendrimers. 
Figure 1.14 illustrates an example of a dual-modality, dendrimer-based molecular 
imaging probe for αvβ3 integrins in a melanoma cell line. The probe exhibited a tumor to 
blood ratio of 3.30 ± 0.03, two hours post injection.
118, 130
      
 
 
1.9.2   Small Molecules  
The synthesis of small molecule multimodality imaging probes is usually 
achieved by the direct fusion of multiple imaging probes, or by attachment of multiple  
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Figure 1.14    An example of a fluorescent/MR dual-modality imaging probe with the 
PAMAM dendrimer core shown in black, gadolinium-EDTA complexes 
(MCC), cRGDfK peptide (targeting αvβ3 integrins) TM, and Alexa Fluor 
594 dye (Dye).
118
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imaging tags to one molecule. While this design maintains a small size for the probe 
overall, it may alter the pharmacokinetics of the parent molecule based on the properties 
of the added imaging tags. In terms of probe excretion, small molecules tend to clear via 
the renal system, while larger molecules (> 5 nm) typically clear though the liver. This 
provides a clear advantage in preventing toxicity associated with long-term liver 
retention. While the short circulation times of smaller probes is undesired, resulting in 
reduced probe uptake, rapid tissue diffusion rates have been observed and may be 
attractive for in vivo applications.
113
 
A number of small molecule probes have already been reported including metal-
chelator-dye conjugates such as Gd-DOTA-rhodamine
131
 and Gd-DO3A-
spironaphthoxazine
132, 133
 (Figure 1.14). Although various efforts have been made in the 
development of MRI-optical small molecule fusions, there are major disadvantages 
associated with this probe design approach. The most important drawback of this 
methodology is the much lower sensitivity of MRI when compared to optical imaging 
techniques, implying that, in a given probe, higher numbers of MRI tags are required to 
produce the same effect as the optical probes. This drawback, however, is minimized in 
vivo due to the lowered sensitivity of optical methods compared to in vitro microscopy. 
The fusion of radioisotopes with optical tags is a more suitable methodology in designing 
multimodality probes because the sensitivities of the involved modalities are in the same 
range. Examples of developed optical/nuclear probes include 
111
In-DOTA-cypate
134
 
(Figure 1.15) and radioiodinated porphyrins (eg. HPPH).
113, 135, 136
         
 
 
39 
  
 
             
 
 
 
 
 
 
Figure 1.15    Structures of 
111
In-DOTA-cypate (left) and Gd-DO3A-spironaphthoxazine 
(right).  
 
The focus of this dissertation is primarily on the development of novel single and 
multimodality molecular imaging probes with an emphesis on PET, SPECT and 
fluorescence imaging. Chapter 2 covers the discovery of novel GLP-1-based PET and 
SPECT imaging probes for the non-invasive visualization of pancreatic islets in vivo. 
Here, syntheses, characterization, radiometal labeling, in vitro and in vivo evaluation (in 
mouse models) of novel tracers, are discussed. Chapter 3 deals with the discovery of a 
new approach for development of multimodality PET/fluorescence imaging probes. With 
the aim of eliminating the need for the attachment of multiple imaging tags in the 
development of multimodality agents, the use of porphyrins is suggested as a fluorescent 
entity that would also act as a radiometal chelator. The development of a model tracer, 
utilizing PPIX as the porphyrin ring of choice, is discussed entailing synthesis, 
characterization, radiolabeling, optical analysis, and in vitro characterization with a breast 
cancer cell line.    Chapter 4 deals with the development of a screening procedure for the 
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discovery of novel biological targeting entities via library screening. This is the first 
example of a fluorescent, cell-based approach for the screening of a peptide library where 
peptide-based targeting entities can be identified directly, post solid-phase synthesis, 
without the need for further modifications. Chapter 5 concludes this dissertation by 
discussing future directions for the developed ideas.     
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CHAPTER 2. Design, Synthesis and In Vitro Characterization of 
Glucagon-Like Peptide-1 Derivatives for Pancreatic 
Beta Cell Imaging 
A section of this chapter has been published in the journal of bioorganic and medicinal chemistry 
Behnam Azad, B. et al. Bioorg. Med. Chem. 2010, 18, 1265-1272 
 
2.1   Introduction 
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia 
and disturbance of carbohydrate, fat, and protein metabolism resulting from defects of 
insulin secretion, insulin action or both.
1
 The relative contribution of these variables, 
however, varies between different types of diabetes. Several processes are involved in the 
development of diabetes including destruction of insulin-producing pancreatic beta cells, 
as well as enhanced resistance to insulin action. It is this insensitivity or lack of insulin, 
which results in abnormalities typically observed in carbohydrate, fat and protein 
metabolism.
2
 Diabetes has emerged as a major health problem worldwide with an 
estimated 285 million people suffering from the disease in 2010. The growth of type 2 
diabetes is expected to increase this number to over 400 million in the next twenty years. 
Considering the projected statistics, the ability to non-invasively monitor the onset of 
diabetes, and its progression into type 2 diabetes, could aid in enhancing our 
understanding of the involved processes, thus allowing for earlier diagnosis and 
treatment.      
Glucagon-Like Peptide-1 (GLP-1) is a peptide hormone produced by intestinal L-
cells in response to nutrient ingestion.
3
 It is produced through the post-translational 
processing of its larger precursor, proglucagon, by the enzyme prohormone convertase 
1/3 and exists largely as the C-terminally amidated form, GLP-1 (7-36).
4
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Other products of this enzymatic degradation are: 1) GLP-2, a peptide involved in 
growth of epithelial cells, 2) glucagon for maintaining blood glucose levels, and 3) 
glicentin related pancreatic peptide (GRPP), a glucagon precursor (Figure 2.1a ). As 
GLP-1 binds to its receptor on the pancreatic beta cell, signaling events trigger the release 
of insulin (Figure 2.1b) in a glucose-dependent manner known as the “incretin effect”.5 
GLP-1 receptor signaling events also lead to the enhancement of beta cell survival 
through stimulation of beta cell growth and differentiation, which plays a role in 
regeneration of beta cell mass.
6
 Therefore, GLP-1 may potentially be a viable and 
powerful candidate in the treatment of Type 2 diabetes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1   An illustration showing (a) major proglucagon degradation products and (b)  
role of GLP-1 in insulin production.   
(a) 
(b) 
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The structure of the GLP-1 receptor classifies it as part of the Family B (II) 
Glucagon-Secretin G Protein-Coupled Receptor (GPCR) super family. The structural 
characteristics of the receptors in this family include a long extracellular N-terminal 
domain, disulfide bridged cysteine residues in the extracellular domains, and several 
glycosylation sites.
7
 Structure-function studies of the GLP-1R have shown that the helical 
region of GLP-1 interacts with the extracellular N-terminal domain of the GLP-1R, while 
the N-terminal 8 amino acids of GLP-1 interact with residues in the extracellular regions 
and transmembrane helices of the receptor.
8
 Such a complex receptor/ligand interaction 
demands consideration of only a limited number of sites on the ligand that can be 
modified for the generation of an imaging probe with GLP-1 as a targeting component. 
Since the structural and biochemical characteristics of the interaction between 
GLP-1 and its receptor have been determined, GLP-1 may be a suitable peptide with 
which to develop peptide-based imaging probes for the detection and monitoring of 
pancreatic beta cell mass in vivo, and thus the onset and progression of diabetes. One 
limiting factor is the short biological half life of GLP-1 (1-2 min) due to rapid enzymatic 
degradation,
7
 as the alanine residue at position 8 is a cleavage site for the plasma protease 
dipeptidyl peptidase-IV (DPP-IV). Thus, in order to develop GLP-1-based therapeutics 
and diagnostics, it is important to increase the biological half life of the parent peptide, 
which can be done through modification of 
8
Ala to 
8
D-Ala.
9, 10
 An alternate approach can 
be the use of exendin-4, a 39-amino acid peptide originally isolated from Heloderma 
suspectum,
11
 which is a more potent and stable GLP-1R agonist with a plasma half life of 
approximately 26 min, largely due to the substitution of a glycine residue for alanine at 
position 8.  
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Considering that GLP-1 receptors are expressed on beta cells in high density, we 
propose that the use of radiolabeled GLP-1, in conjunction with non-invasive imaging 
techniques SPECT or PET, can provide a method of studying beta cell mass in vivo. This 
hypothesis is supported by a recent report on the generation of the probe [
40
Lys (Ahx-
DTPA-
111
In)NH2]exendin-4, which was shown to target the GLP-1 receptor for the 
molecular imaging of insulinomas in transgenic Rip1Tag2 mice.
12
 In terms of GLP-1 
peptides, until now, radioiodination has been the only method reported for GLP-1 
radiolabeling. However, iodinated peptides, such as [
123
I]GLP-1 for detection of 
insulinomas, have been reported to be unsuitable as a result of the instability of the 
radioiodine label in vivo.
13
 Here we report radiometal and radiofluorinated derivatives of 
GLP-1 with increased structural stability and optimal binding affinity for beta cell 
imaging.  
 
 
2.1.1   Selection of Suitable Metals  
Radiometal-labeled ligands have commonly been used in molecular imaging with 
both PET and SPECT modalities. Radiopharmaceuticals labeled with metal radionuclides 
are typically injected into patients in order to diagnose and monitor biological processes 
in cancers, infections, thrombosis, kidney / liver abnormalities, as well as cardiological 
and neurological disorders. Radiometal agents are also used to monitor cancer therapy 
and targeted radiotherapy treatments. Metals utilized in radiopharmaceuticals range in 
half-life from 10 min for 
62
Ga to several days in case of 
67
Ga, thus providing a wide range 
of options to meet such criteria.
14
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Design of radiometal-based imaging agents requires sufficient understanding of 
the redox properties, stability, stereochemistry, charge and lipophilicity of radiometal 
complexes because, in most cases, this information would help explain the observed in 
vivo behavior of the developed compounds. For instance, the clearance path of negatively 
charged compounds is typically through the kidneys, while positively charged 
compounds tend to accumulate in the heart. In brain imaging, having an overall neutral 
complex is a requirement for crossing the blood brain barrier. Lipophilic complexes have 
been commonly observed to clear through the hepatobiliary system with fatty tissue 
accumulation. Stereochemistry plays an important role, in temrs of ligand receptor 
interaction, when targeting surface receptors.
14
    
 
 
2.1.2   Coordination Chemistry of Indium and Gallium 
Under physiological conditions, the oxidation state of the group 13 metals indium 
and gallium is +3, making it the only relevant oxidation state for radiopharmaceutical 
sciences. Complexation of ligands to In and Ga is carried out based on the 
hardness/softness of the acid/base.
15
 While gallium, being slightly harder than indium, 
would chelate oxygen, nitrogen or sulfur atoms, indium would prefer neutral nitrogen or 
negatively charged sulfur atoms. Coordination spheres of gallium could include 3, 4, 5, or 
6 ligands while indium coordination could include up to seven ligands due to its larger 
ionic radius. Octahedral complexes of both metals, however, have been reported to be 
thermodynamically and biologically more stable.
14, 16-18
  
A major consideration in the chemistry of trivalent indium and gallium is their pH 
dependent hydrolysis. Free hydrated Ga(III) is only stable under acidic conditions with 
65 
  
the insoluble Ga(OH)3 forming as the major product between pH 3 and 9.5. Reactions 
carried out in solutions with pH > 9.5 result in the formation of soluble gallate ions 
[Ga(OH)4
-
]. Similarly, free indium(III) is stable in slightly acidic pH solutions (pH = 4-5) 
when it exists as a hexaqua ion, while it undergoes extensive hydrolysis below pH 3.4, 
and forms soluble hydroxides under basic conditions.
19
 Considering that the rate of 
hydrolysis is much faster than that for metal-complexation, a careful selection of ligands 
and optimization of pH levels is a significant requirement. In general, indium(III) and 
gallium(III) complexes have been reported to exhibit high thermodynamic stability and 
biological inertness (no exchange with transferrin), especially in cases utilizing 
multidentate chelators.
14, 18
  
 
 
2.1.3   Indium and Gallium Radioisotopes 
The metals gallium and indium have several medically useful radioisotopes that 
can be used for diagnostic imaging, the most widely used of which are Ga-67 and In-
111.
20
 The later has been employed in tumor imaging (
111
In-DTPA-octreotide),
21
 tumor 
pre-targeting (
111
In-DTPA-biotin),
22
 folate receptors imaging (
111
In-DTPA-folate),
23
 
somatostatin receptor imaging (
111
In-DOTA-CCK-8),
24
 thrombus (
111
In-oxine),
25
 and 
inflammation (
111
In-white blood cells)
26
 imaging.
14
    
The use of Ga-68 for positron diagnostic imaging has also gained significant 
interest owing to its convenient half-life and its wide availability from radionuclide 
generators.
27-31
 An example of gallium based imaging agents is 
68
Ga-Citrate which has 
been used in quantification of pulmonary vascular permeability.
32
 The use of PET allows 
quantification that otherwise would not be possible with 
67
Ga and gamma scintigraphy. 
66 
  
There have also been advances in development of radiotracers for myocardial (eg. 
68
Ga-
[(4,6-MeOssal)2BAPEN]
+
),
33
 brain (eg. 
68
Ga-THM2BED),
34
 tumor (eg. 
68
Ga-
octreotide),
35
  and Thrombus (eg. 
68
Ga-platelets)
36
 imaging.      
As a result, this work employed both indium-111 and gallium-68 in the 
development of SPECT and PET oriented molecular imaging probes for beta cell 
imaging. Indium-111, produced by the 
112
Cd (p,2n)
111
In nuclear reaction,
37
 was 
purchased, whereas gallium-68 was obtained from an in house Eckert and Ziegler 
68
Ge/
68
Ga radionuclide generator coupled to a modular lab unit for automated synthesis. 
 
 
2.1.4   Radiometal-Chelator Selection  
One class of chelators commonly used for the radiometal labeling of peptides are 
cyclen derivatives, such as DOTA,
38-40
 which are inert and thermodynamically stable, 
making them good candidates for radiolabeling of peptides and antibodies.
40, 41 
Examples 
of chelator-conjugated peptides include DOTA-labelled somatostatin analogues (eg. 
DOTA-NOC (1-Nal3-octreotide),
42
 and RGD peptides.
43
 A review by De León-
Rodríguez and Kovacs was recently published on DOTA-peptide conjugates and their 
applications.
40
 To date, DOTA has not been employed as a chelator for the radiolabeling 
of GLP-1. The conjugation of DOTA to a peptide using solid-phase chemistry, the most 
suitable synthetic approach for peptides, requires ligands that are compatible with the 
organic solvents commonly used in solid-phase peptide synthesis (SPPS). The 
commercially available tris-tBu-DOTA (Figure 2.2), satisfies these requirements and can 
be conjugated, via an unprotected carboxylic acid, to free amino groups using 
tetramethyluronium coupling agents such as HBTU (O-benzotriazole-N,N,N’,N’-
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tetramethyl-uronium-hexafluoro-phosphate) or HATU (2-(1H-7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium). Both indium and 
gallium have been shown to form stable complexes with cyclen derivatives. Therefore 
tris-tBu-DOTA was selected for chelation of both metals.  
 
 
 
 
Figure 2.2  Structure of tris-tBu-DOTA.  
 
 
2.1.5   Radiofluorination  
Considering the rapid blood clearance of peptides, high signal to noise ratios can 
often be achieved in reasonably short time periods. As a result, short-lived PET isotopes 
are potential candidates for labeling of bioactive peptides. Fluorine-18, in particular, is an 
ideal candidate for such applications with a half-life of 110 minutes, which is also 
sufficient for tracer transport. This isotope can be produced in large quantities and 
exhibits a low positron energy (0.64 MeV), reducing radiation dose to patients while still 
providing high resolution images. Table 2.1 lists commonly used radiofluorinated 
peptide-based compounds in oncology.
44-52
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Radiotracer Application 
[[
18
F]-Nle
4
, D-Phe
7
]-α-MSH α-MSH receptors (eg. melanomas) 
[
18
F]-NT(8-13) NT receptors  
[
18
F]SAA-RGD αvβ3 integrin expression 
[
18
F]Fluorobenzoyl-RGD Integrin receptors  
[
18
F]C-peptide Specific cell-membrane receptors  
[
18
F]-ET-1 Endothelin receptors  
[
18
F]FNleLFNleYK Infection/inflammation 
  
Table 2.1    Examples of 
18
F-labeled peptide-based imaging tracers. 
 
Ideal conditions for radiofluorination procedures are given in Table 2.2. The 
initial step in all fluorination reactions involves the pre-activation of cyclotron-produced 
aqueous [
18
F]fluoride by evaporation from an added base (K2CO3/Kryptofix-222 and 
Bu4N
+
). Subsequent reactions are then carried out under strong basic conditions, which 
are not suitable for compounds containing amine/thiol reactive groups or complex 
bioactive molecules. Although, fluorine-18 labeling procedures for peptides are often 
time-consuming and laborious, efficient radiolabeling reactions have been reported using 
the prosthetic group approach.
44
 This is especially significant considering that the direct 
fluorination of biomolecules is not possible, leading to denaturing and decomposition of 
labile substrates.
53
 Prosthetic groups can be conjugated by various means such as 
acylation (eg. methyl 2-[
18
F]fluoropropionate),
54
 amidation (eg. 1-[4-
([
18
F]Fluoromethyl)benzoyl]-aminobutane-4-amine),
55
 imidation (eg. 3-[
18
F]Fluoro-5-
nitrobenzimidate),
56
 alkylation (eg. N-(p-[
18
F]Fluorophenyl)maleimides),
57
 and 
photochemical conjugation (4-Azidophenacyl-[
18
F]fluoride).
58
 Among all prosthetic 
groups reported to date, use of N-succinimidyl 4-[
18
F]fluorobenzoate ([
18
F]SFB) appears 
to be the most suitable approach in radiofluorination of biomolecules as it has been 
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reported to result in higher yields and biologically more stable products.
58
 As a result, the 
prosthetic group methodology with [
18
F]SFB was employed in this work for the 
development of GLP-1 based, Fluorine-18 PET tracers.
44
                 
 
Simple, quick and efficient procedure 
Few preparation steps 
No influence of the labeling agent on the biological activity of the targeting entity 
Mild reaction conditions (eg. pH, temperature) to prevent decomposition 
Simple radiosynthesis of the prosthetic group 
Sufficient chemical reactivity of the prosthetic group 
Formation of desired products at tracer concentrations 
Minimal side-reactions 
Few purification steps 
High specific activity product 
 
Table 2.2     Basic requirements of ideal radiofluorination procedures.
44
  
 
This work utilized both radiometal and radiofluorinated derivatives of GLP-1 in 
order to develop probes with enhanced structural stability and optimal binding affinity for 
beta cell imaging. Furthermore, various GLP-1 derivatives were prepared in order to 
determine the best substitution site for the prosthetic group or chelator to maintain 
optimal binding affinity for GLP-1 receptors. 
 
2.2.     Experimental Procedures 
Common solvents and reagents were purchased from VWR, Fisher Scientific, or 
Sigma-Aldrich and used as received, unless stated otherwise. Sterile, deionized water was 
used in all aqueous procedures. All Fmoc protected amino acids, except Fmoc-Lys(mtt)-
OH (Nova Biochem), and HBTU were obtained from Peptides International. Fmoc-Rink 
amide MBHA resin (4-(2’,4’-Dimethoxyphenyl-(9-Fluorenylmethoxycarbonyl)-
aminomethyl)-phenoxy-acetamido-norleucyl-4-Methyl Benzhydrylamine resin), and 
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Boc-His(Boc)-OHDCHA (dicyclohexylamine) were obtained from Nova Biochem. The 
hydrophilic linker 2-[2-(2-aminoethoxy)ethoxy]acetic acid (AEEA) was synthesized in 
our laboratory.
59
 DOTA-tris(tBu)-ester was obtained from CheMatech. Indium trichloride 
tetrahydrate (99.99%) was obtained from Strem Chemicals. Indium-111 and [
125
I]-
exendin were obtained from MDS Nordion and PerkinElmer Inc. respectively. 
[
18
F]Fluoride was obtained from Hamilton Health Sciences. RP-C18 Sep-Pak SPE 
cartridges were obtained from Waters. CHO/GLP-1R and INS-1 832/13 cells were 
provided by Dr. Michael Wheeler from University of Toronto and Dr. Christopher 
Newgard from Duke University respectively. Gallium-68 generator and all automated 
synthesis modules were purchased from Eckert and Ziegler.   
 
 
2.2.1   Peptide Syntheses 
Fmoc-based solid-phase peptide synthesis was carried out using an APEX 396 
autosynthesizer (AAPPTEC) with 0.05 meq of 0.27 mmol/g Fmoc-Rink amide mBHA 
resin and a 3-fold excess of the protected amino acids. Fmoc removal, carried out with 
20% piperidine in DMF (N,N-dimethylformamide) over two cycles (10 and 20 min), was 
followed by amino acid activation with 3 eq HBTU and 6 eq DIPEA (N,N-
diisopropylethylamine) (10 min) and subsequent coupling over 30 and 120 min cycles.  
Methyl trityl deprotection was carried out in a glass peptide reaction vessel using 
5% triisopropylsilane (v/v) + 2% trifluoroacetic acid (v/v)  in CH2Cl2 over 3 min and 
repeated 10 times. Coupling of DOTA/AEEA to this site, or the coupling of DOTA to 
AEEA, followed the same methodology used in amino acid coupling, however the 
coupling times were increased to 18 and 24 hours for AEEA and DOTA respectively. In 
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preparation of fluorescent GLP-1 analogues, conjugation of FITC to Mtt-deprotected 
37Lys was carried out using a 4 fold excess of FITC and DIPEA in DMF. This 
conjugation reaction was monitored using Kaiser tests and was completed in 23 hours   
Microcleaved samples were also used to monitor reaction progress and peptide purity via 
HPLC.  
Full deprotection of synthesized peptides was accomplished using a solution of 
88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane (v/v) over 6 
hours. The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME) 
and centrifuged (2200 rpm for 15 min). After removing the resulting supernatant, the 
peptide pellet was rinsed with TBME, vortexed and centrifuged again (2200 rpm for 15 
min). The supernatant was removed, then the peptide pellet was dissolved in water, 
frozen at 78 
o
C and lyophilized.   
 
   
2.2.2   Purification by RP-HPLC / ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (Grace 
Vydac Protein/Peptide RP-C18 column 4.6 x 250 mm, 5 μm). This system was equipped 
with a Waters 600 controller, Waters Prep degasser, and Waters MassLynx software 
(version 4.1). Employed mobile phases were 0.1% CF3CO2H in water (eluent A) and 
0.1% CF3CO2H in CH3CN (eluent B). The linear gradient used was 30-50% of B with a 
flow rate of 1.5 mL min
-1
 over 20 min. The column eluate was monitored using a Waters 
2998 Photodiode array detector set at 220 and 254 nm. 
Peptides were purified using a reverse-phase preparative HPLC column (Grace 
Vydac Protein/Peptide RP-C18 column 22.0 x 250 mm, 10 μm) on the same system 
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mentioned above. The detection method along with eluents and gradients were the same 
as those stated above, with the exception of the flow rate being set at 20 mL min
-1
. The 
collected fraction was then lyophilized to a solid and subsequently analyzed by ESI-MS 
(electrospray ionization mass spectrometry) (Waters Micromass Quattro Micro
TM
 API). 
Purity of final products was determined by analytical RP-HPLC (reverse-phase high 
performance liquid chromatography).    
 
 
2.2.3   
113/115
In Labeling 
In a typical reaction, 5 mg of the GLP-1 analogue, 3 mL of pH 5 NaOAc / HOAc 
buffer, and 7 mg of InCl34H2O (0.02 mmol) were placed in a 25 mL glass round bottom 
flask. The reactants were dissolved by sonication at 25 
o
C. The reaction was then carried 
out at 70 
o
C for 30 min. The resulting reaction mixture was allowed to cool before 
purification by a light C18 RP sep-pak
© 
(conditioned with 3 mL of ethanol and 10 mL of 
H2O). After passing the reaction mixture through the sep-pak
©
, 10 mL of water was used 
as eluent in order to wash out residual unreacted InCl34H2O. A 10 mL aliquot of 0.1% 
TFA in CH3CN was used to wash out the labeled product. The resulting solution was then 
mixed with 10 mL of H2O (to lower the % component of acetonitrile), frozen at -78 
o
C 
and subsequently lyophilized.  
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2.2.4   
111
In Radiolabeling 
To a clean conical glass vial was added 20 µL of the prepared GLP-1 analogue (1 
mg/ mL of pH 5 NaOAc / HOAc buffer). This aliquot was dissolved in 200 µL of the 
buffer (10 fold dilution to obtain µM concentrations), to which 5.63 mCi of 
111
InCl3 was 
added. The reaction mixture was then heated at 70 
o
C for 30 minutes, before purification 
by a RP-C18 SPE Sep-Pak cartridge (conditioned with 5 mL of ethanol and 15 mL of 
water). After passing the reaction mixture through the sep-pak
©
, 10 mL of water was used 
as eluent in order to wash out residual unreacted InCl3. A 5 mL aliquot of EtOH was used 
to wash out the radiolabeled product. The Sep-Pak eluate was evaporated on a rotary 
evaporator prior to in vitro studies. The reaction progress and product purity was 
analyzed using analytical RP-HPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18 
column) coupled to a gamma detector. This system employed a Waters 1525 Binary 
HPLC pump, Waters 2487 dual  absorbance detector, Waters In-Line degasser and 
Breeze software (version 3.30).   
 
 
2.2.5   
69/71
Ga Labeling 
In a typical reaction, 10 mg of GLP-1 analogue was dissolved in pH 4 NaOAc / 
HOAc buffer. Chelation was carried out using a two-fold excess of anhydrous GaCl3 at 
75 
o
C over 30 minutes. Resulting mixture was cooled prior to purification by a plus C18 
RP sep-pak
©
 (conditioned with 6 mL of ethanol and 25 mL of water). After passing the 
reaction mixture through the sep-pak
©
, 10 mL of water was used as eluent in order to 
wash out residual unreacted GaCl3. A 6 mL aliquot of EtOH was used to wash out the 
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labeled product. The resulting solution was then dried on a rotary evaporator, mixed with 
10 mL of H2O, frozen at -78 
o
C and subsequently lyophilized overnight.    
 
2.2.6   
68
Ga Radiolabeling 
To a clean glass microwave vessel was added 100 µL of GLP-1 analogue solution 
(1 mg/mL in pH 3.5 HEPES buffer). This aliquot was dissolved in 900 µL of the buffer 
(10 fold dilution to obtain final solution with µM concentrations), to which 3 mCi 
68
GaCl3 was added, freshly eluted from the Ge-68/Ga-68 generator using 3 mL of 0.1 M 
HCl. Purification and isolation of 
68
Ga was achieved using a Phenomenix Strata-X-C 33u 
polymeric strong cation exchange column (30 mg/mL) with 0.05 N HCl in Acetone as the 
eluent. The reaction mixture was then heated in the reactor of the automated synthesis 
module at 80 
o
C for 30 minutes, prior to sep-pak
©
 purification using a light RP-tC18 SPE 
Sep-Pak cartridge
©
 (conditioned with 3 mL of ethanol and 10 mL of water). After passing 
the reaction mixture through the sep-pak
©
, 3 mL of water was used as eluent in order to 
wash out residual unreacted 
68
Ga materials. A 2 mL aliquot of EtOH was used to wash 
out the radiolabeled product. After evaporation of the solvent on a V-10 1.6 Biotage
®
 
vortex and vacuum evaporation system. The reaction progress and product purity was 
analyzed using analytical RP-HPLC (Sunfire
TM
 RP-C18 column 4.6 x 150 mm, 5 μm) 
coupled to a gamma detector, prior to further use in animal studies. HPLC system 
employed a Waters 1525 Binary HPLC pump, Waters 2487 dual  absorbance detector, 
Waters In-Line degasser and Breeze software (version 3.30).   
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2.2.7   Synthesis of Modified GLP-1 analogue (9) 
GLP-1 derivatives were prepared using Fmoc solid phase methodology as 
previously mentioned. Glysine 37 was replaced with Fmoc-Lys(Alloc)-OH, while Fmoc-
Lys(Mtt)-OH residues used in positions 26 and 34 were acylated. In a typical experiment, 
0.05 meq of peptide-loaded resin was swollen in DMF. Methyl trityl deprotection of Lys 
26 and 34 side chains was carried out in a glass peptide reaction vessel using 5% 
triisopropylsilane (v/v) + 2% trifluoroacetic acid (v/v)  in CH2Cl2 over 3 min (repeated 
x10 ). The resin was washed thoroughly with DMF and DCM respectively. A 7 mL 
solution of 10% acetic acid anhydride in DMF was then added to the resin followed by 
shaking over 15 min (repeated x5). Completion of acylation reaction (ie. presence of free 
amines) was monitored by Kaiser tests. DOTA coupling then proceeded as stated 
previously.            
 
 
2.2.8   Synthesis of [
19
F]FB-GLP-1 
Synthesis of [
19
F]Fluorobenzoic acid (4-FB) was carried out using a solid-phase 
methodology. In a typical synthesis, 0.05 meq of fully protected GLP-1 analogue on rink 
amide resin was swollen in DMF over 10 min. Methyl trityl deprotection at position 37 
was carried out in a glass peptide reaction vessel using 5% triisopropylsilane (v/v) + 2% 
trifluoroacetic acid (v/v)  in CH2Cl2 over 3 min (repeated 10 times). In certain instances 
Lys(alloc)-OH was employed in position 37. Alloc deprotection was carried out by initial 
treatment of the resin with 20 eq of PhSiH3 in DCM for 3 min. This was followed by 
addition of 0.25 eq of Pd(PPh3)4 in DCM and mixing over 30 min. This process was 
repeated twice prior to prosthetic group conjugation.     
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Coupling of 4-FB to this site was carried out using 4 eq of 4-FB and HATU and 6 
eq of DIPEA in 5 mL of DMF over 4 hours. Microcleaved samples were used to monitor 
reaction progress and peptide purity via HPLC. Full deprotection was accomplished using 
a solution of 88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane 
(v/v) over 6 hours. The cleaved peptides were then precipitated using TBME and 
centrifuged (2200 rpm for 20 min). After removing the resulting supernatant, the peptide 
pellet was rinsed with TBME, vortexed and centrifuged again (2200 rpm for 20 min). The 
supernatant was removed, peptide pellet dissolved in water, frozen at -78 
o
C and 
lyophilized overnight. Purification of the peptide was carried out using a reverse-phase 
preparative HPLC column (Grace Vydac Protein/Peptide RP-C18 column 22.0 x 250 
mm, 10 μm).       
  
 
2.2.9   Synthesis of t-butyl-N,N,N-trimethylammoniumbenzoate triflate 
In a typical reaction, 700 mg of 4-dimethylaminebenzoic acid was added to 50 
mL of THF and cooled to 0 
o
C for 15 min. This was followed by drop wise addition of 
1.3 mL of trifluoroacetic anhydride and stirring for 35 minutes. After addition of 8 mL of 
t-BuOH in one portion, the mixture was warmed up to room temperature and stirred over 
2 hours. This mixture was then poured into 250 mL of saturated NaHCO3 and extracted 
(3x) with dichloromethane. Organic layers were combined, evaporated using a rotary 
evaporator, dried with MgSO4 and passes through a silica gel plug. The product was 
subsequently eluted using 60 mL of DCM, and evaporated to give a yellow oil. This oil 
was redissolved in nitromethane and cooled to -30 
o
C for 20 min. A 500 µL aliquot of 
methyl triflate was then added drop wise to the reaction mixture, which was warmed up 
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to 0 
o
C and stirred over 1 hour. The reaction mixture was poured into 200 mL of diethyl 
ether causing the precipitation of the desired product as a white powder, which was 
isolated by suction filtration and washed with cold diethyl ether. The dried product was 
analyzed using 
1
H NMR and was shown to not require further purification. Typically 1 g 
of product was obtained indicating a 68% yield.   
 
              
2.2.10   Synthesis of 4-[
18
F]FB and 4-[
18
F]SFB 
Prior to the start of reaction, the obtained [
18
F]Fluoride sample was dried via 
azeotropic evaporation with anhydrous acetonitrile. A typical reaction involved the 
addition of 5 mg (13 mmol) of the triflate salt to 1 mL of anhydrous CH3CN containing 
80 mCi of [
18
F]Fluoride. The mixture was heated at 90 
o
C over 10 min. A 500 µL aliquot 
of 1 M HCl was added and the reaction mixture heated at 100 
o
C for 5 min. After cooling, 
the mixture was diluted with 12 mL of deionized water and passed through a RP-C18 
light Chromafix cartridge. The product was eluted with 7 mL of acetonitrile, followed by 
addition of 500 µL of 45% Me4NOH. The solvent mixture was evaporated at 100 
o
C 
under a nitrogen stream and product was assayed and analyzed using an analytical RP-
HPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18 column) coupled to a gamma 
detector. Decay-corrected radiochemical yields were 35±5% with radiochemical purities 
> 98%. 
The synthesis of Succinimydyl 4-[
18
F]Fluorobenzoic acid involved the activation 
of [
18
F]FB with 15 mg of TSTU in 500 µL of anhydrous acetonitrile at 90 
o
C over 4 min. 
After cooling and addition of 10 mL of 5% aqueous acetic acid, the reaction mixture was 
passed through a RP-C18 Chromafix cartridge. Unreacted materials were washed out of 
78 
  
the cartridge using 2 mL of a 65:35 water:acetonitrile solution. The product was eluted 
with 3 mL of acetonitrile, dried using a rotator evaporator, assayed and analyzed using an 
analytical RP-HPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18 column) coupled to a 
gamma detector. Activation by HATU was carried out using the same methodology. 
 
 
2.2.11   Solid-phase Synthesis of 37-Lys-[
18
F]FB-GLP-1(7-37) 
Coupling of [
18
F]FB was carried out on resin using Mtt-deprotected GLP-1 
derivative, with HATU in DMF at 50 
o
C over 15 min. Resin batch was then drained, 
washed with DCM, and assayed. Complete deprotection and cleavage from the resin was 
then achieved using 90% TFA and scavengers at 50 
o
C over 20 min. The resulting 
cocktail was then evaporated on a rotary evaporator, counted and analyzed by analytical 
HPLC as mentioned above. In the case of [
18
F]SFB, the reaction was carried out (on 
resin), in 500 µL of DMF at 50 
o
C over 15 min. Deprotection, cleavage from resin and 
subsequent analysis steps were carried out as mentioned above.                 
 
 
2.2.12   Binding Assays 
All GLP-1 receptor binding studies were conducted using Chinese hamster ovary 
cells stably transfected with the human GLP-1 receptor (CHO/GLP-1R), generously 
donated by Dr. Michael Wheeler (University of Toronto). Receptor binding was 
measured by the displacement of [
125
I]-exendin-4 with  increasing concentrations of the 
synthesized 
113/115
Indium or 
69/71
Ga-labeled GLP-1 analogues, using a previously 
published method.
60
 Briefly, CHO/GLP-1R cells were cultured in Dulbecco’s Modified 
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Eagle’s Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (Invitrogen). 
On the day of the experiment, cells were rinsed 2X with warm Hank’s buffered saline 
solution (HBSS) and dissociated in HBSS containing 2 mM EDTA. Approximately one 
million cells were incubated for 60 min at 37 
o
C in binding buffer (DMEM containing 
0.1% Trasylol (Bayer) and 0.1% bovine serum albumin (Sigma), pH 7.4), 0.77 µmol 
[
125
I]exendin-4 (Amersham) and variable concentrations of each GLP-1 analogue (10
-5
 to 
10
-11
 M). After incubation, cells were centrifuged at 2800 rpm for 15 min. After removal 
of the supernatants, the cell pellets were washed with 200 µL of cold binding buffer and 
re-centrifuged before the final pellet was counted in a gamma counter. Binding curves 
and IC50 (half maximal inhibitory concentration) values were generated using MS Excel, 
Sigma Plot, and Origin Lab 8.    
 
 
2.2.13   cAMP Studies 
Activation of the GLP-1 receptor by the peptide analogues was assessed by 
stimulation of cAMP using a  previously published method.
60
 Briefly, CHO/GLP1R cells 
were plated at a density of 1x10
5
 cells/well in a 24-well plate 48 hours prior to the day of 
the experiment. Cells were incubated for 30 min at 37 
o
C in DMEM containing 1 µM 3-
isobutyl-1-methylxanthine (IBMX; Sigma) and 10 nM of the peptide analogues. Media 
were removed, cells were rinsed twice with cold HBSS and scraped in 200 µL of 80% 
ethanol. cAMP levels were measured using a cAMP radioimmunoassay kit (Perkin 
Elmer, Shelton CT) as per the manufacturer’s instructions. Differences between basal and 
stimulated cAMP levels were analysed using a one-way ANOVA followed by Student’s 
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t-test, and differences in fold stimulation were determined using a one-way ANOVA 
followed by Tukey’s post-hoc test. Significance was set at p < 0.05 for all analyses.  
 
2.2.14   In Vitro Imaging 
INS-1 832/13 cells were plated in 6-well plates at a density of one million cells 
per well. Two wells did not receive any radiolabeled peptide; two wells were incubated 
with 50 µCi [
111
In]-8 for 30 min at 37 
o
C; and two wells were incubated with 50 µCi 
[
111
In]-8 and 1 µM cold exendin-4. After the incubation period, media were removed, 
cells were rinsed twice with cold HBSS and covered with 500 L culture media. Cells 
were imaged for 30 min with a GE Millenium II gamma camera using a medium-energy 
general purpose collimator. Images were acquired and analyzed using GE Xeleris 
software. 
 
 
2.2.15   In Vivo Imaging 
In vivo imaging studies were conducted in C57BL/6 mice following tail vein 
injection of 0.3-3.5 MBq of 
111
In- or 
68
Ga-7. Mice were euthanized 3 min or 4 hours post 
injection. The pancreata and other organs were then removed and assayed. 
Biodistribution was calculated as % injected dose/g.   
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2.3      Results and Discussion 
2.3.1   Design of GLP-1 Analogues  
The objective of this study was to develop novel GLP-1 analogues exhibiting 
optimal binding affinity for GLP-1 receptors thus allowing for the imaging of pancreatic 
islets. The primary difficulty in attaching DOTA to GLP-1 is interference with peptide-
receptor binding caused by the addition of a metal-complex to the peptide structure. 
Therefore, an integral part of this research project was the determination of optimal 
attachment sites for the metal chelator in order to circumvent negative impacts on the 
binding affinity of the peptide. Figure 2.3 illustrates one of the peptide derivatives before 
labeling. Improvement in structural stability of the developed GLP-1 analogues was 
achieved by substitution of L-Ala at position 8 with D-Ala, which is a modification 
previously reported to increase the resistance of this peptide to degradation by DPP-IV.
9
 
Other substitutions at this position, namely 
8
Aib, 
8
Gly, 
8
Ser, and 
8
Thr, have also been 
reported to increase the structural stability of GLP-1; however, the latter three 
substitutions have a negative impact on the binding affinity and potency of the peptide as 
an endocrine hormone.
61
  
 
 
 
 
 
Figure 2.3   Structure of 
37
Lys-DOTA-GLP-1. 
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A report by Lee and coworkers showed that covalent coupling of PEG 
(polyethylene glycol) to specific sites on GLP-1 may improve the overall therapeutic 
effect of the peptide while maintaining its biological activity.
62
 For instance, PEGylated 
GLP-1 conjugates, PEG2K-N
ter
-GLP-1 and PEG2K-
26/34
Lys-GLP-1, were prepared and 
analyzed in vitro. The latter was a mixture of derivatized peptide at positions 26 and 34 
which could not be separated. The pharmacokinetic profile of each peptide was studied in 
vivo, with the finding that while PEGylation at 
34
Lys did not increase the biological half-
life of the peptide, it did increase its potency in vivo.
62
 Another report by Madsen and 
coworkers explored the structure-activity relationship of Liraglutide analogues, coupled 
to fatty acids, with respect to potency on cloned human GLP-1 receptors. The authors 
noted that in most cases, long and bulky fatty acids decreased the potency of the 
peptide.
59
 Knudsen et al. reported that GLP-1 can be derivatized at the C-terminal part of 
the peptide, with both short/long fatty acids and amino-acid derived spacers, and still 
maintain its potency.
63
      
In order to reduce any steric effects imposed by the macrocyclic DOTA ring on 
the binding site of the peptide derivatives, a short polyethyleneglycol chain, 2-[2-(2-
aminoethyl)ethoxy]acetic acid (AEEA), was employed as a spacer to separate the metal-
chelator complex from the main peptide chain. Considering that this spacer was to be 
used at varying sites on the peptide chain, a short PEG-length was selected in order to 
minimize negative impacts on the binding affinity of the peptide.
63
 The AEEA spacer was 
synthesized according to a published procedure.
64
  
There have been a number of reports identifying the key residues within the 
sequence of GLP-1(7-37) that are critical for optimal binding and proper biological 
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functionality. Deletion of the N-terminal 8 amino acids, or substitution of residues within 
the N-terminal 10 amino acids, resulted in a dramatic reduction in receptor affinity
8, 60
. 
Alanine scanning experiments have shown that amino acids in positions 7, 10, 12, 13 and 
15 were directly involved in receptor binding and activation, whereas those in positions 
28 and 29 maintained the secondary structure of the peptide necessary for receptor 
recognition.
65
 These studies therefore highlight the importance of the N-terminal region 
of GLP-1 in binding to and activating its receptor. Leger and coworkers synthesized a 
number of GLP-1 HSA (human serum albumin) analogues and subsequently tested the 
stabilizing effect of bioconjugation in the presence of DPP-IV, as well as receptor 
binding and activation.
66
  From this study, they concluded that the C-terminus is the best 
point of modification both in terms of stability, especially with D-Ala at position 8, and 
biological activity.
66
 Figure 2.4 summarizes the results that have been reported on 
structure-activity relationships of GLP-1. 
67
 
 
 
 
 
 
Figure 2.4   A schematic of the structure activity relationship of GLP-1.  
 
According to the reported Ala scans, structural modification at positions 14, 16-
18, 20, 22, 27 and 30-35 may be possible without having a major impact on the binding 
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affinity of the peptide. The HSA study showed that the only site suitable for side group 
modification with bulky ligands is position 37 (C-terminus).
66
 However, a report on GLP-
1 PEGylation,
62
 indicated that positions 26 and 34 could also be functionalized with 
bulky ligands without a major impact on binding affinity of the peptide. Therefore, based 
on the structure-activity relationships reported to date along with the reported 
modifications discussed above, we selected positions 22, 26, 34 and 37 as sites for the 
attachment of DOTA to GLP-1. To the best of our knowledge, substitution of large 
ligands at position 22 has not been previously reported. The modification of the peptide 
at positions 22 and 37 required substitution of Gly (originally at this site), with Lys, 
whereas those at positions 26 and 34 already contained a Lys residue.   
 
 
2.3.2   Synthesis of Indium-GLP-1 Analogues    
GLP-1 analogues were synthesized using standard Fmoc-SPPS methods with an 
automated multi-well synthesizer. A representative synthetic route is described in 
Scheme 2.1, illustrating the preparation of 
37
Lys-DOTA-GLP-1(7-37) and the related 
analogue containing a spacer between the peptide and the DOTA, 
37
Lys-AEEA-DOTA-
GLP-1(7-36). N-Fmoc removal was achieved using 20% v/v piperidine in DMF with the 
Kaiser test being used to identify the presence of free primary amino groups, hence 
determining the proper duration for Fmoc deprotection. Amino acids with reactive side 
chains were protected with acid labile orthogonal protecting groups such as OtBu, tBu, 
Trt and Pbf. The site of DOTA attachment, the ε-amine of a lysine side chain positioned 
at amino acid 22, 26, 34, or 37, was protected with the temporary protecting group 4-
methyltrityl (Mtt), which was later removed using a solution of 2% TFA in DCM 
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(dichloromethane) with triisopropylsilane as a scavenger. Other lysine residues in the 
peptide main chain were protected with Boc groups, which are much less acid labile. 
Small samples of the peptide in preparation were taken at varying intervals and, after full 
deprotection, were subsequently analyzed using ESI-MS and RP HPLC. Typical yields 
obtained for the purified GLP-1 analogues were 10-15%. The purity of the peptides along  
 
 
  
 
 
 
 
 
 
 
 
 
Scheme 2.1  Employed synthetic pathway for the preparation of 
37
Lys-DOTA-GLP-1 and 
37
Lys-AEEA-DOTA-GLP-1(7-37): (a) 20% pip/DMF; (b) Fmoc Amino 
Acid, HBTU, DIPEA; (c) 2% TFA, triisopropylsilane; (d) Fmoc-AEEA-OH, 
HBTU, DIPEA; (e) DOTA(tBu)3, HBTU, DIPEA; (f) 88% TFA + 
scavengers.  
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with their respective ESI-MS characterization are given in Table 2.3. While purification 
of most products resulted in purities in excess of 90%, due to the difficult nature of 
preparing these lengthy sequences and the very similar HPLC retention times of peptide 
byproducts formed during syntheses, compound 5 was obtained with only an 85% purity. 
Initial labeling experiments were carried out using naturally occurring indium-
113/115 (Scheme 2.2), in order to obtain IC50 values, synthesize HPLC standards, and 
determine radiolabeling conditions while preventing unnecessary exposure to radiation. 
High temperatures are required for this reaction in order to speed up the formation of the 
product. In addition, a sodium acetate buffer was employed in order to maintain the pH at 
the desired level, thus preventing the formation of insoluble indium oxides.
68
 Products 
were purified using preparative HPLC and subsequently characterized using ESI-MS, 
which in all instances indicated complete labeling of peptides. Final compounds were 
analyzed by RP-HPLC for purity determination prior to biological evaluation.  
In total, eight novel GLP-1 analogues containing indium were prepared, with four 
positional variations (22, 26, 34, 37), each position being prepared with and without the 
AEEA spacer. Figure 2.5 illustrates examples of UV and MS spectra obtained for 
compound 7.  
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# Peptide Purity 
(%) 
Calculated  
(m/z) 
Observed  
(m/z) 
1 22Lys-In-DOTA-GLP-1(7-36) 90.0 1290.2  [M+3H]
3+ 1290.3  [M+3H]3+ 
2 22Lys-AEEA-In-DOTA-GLP-1(7-36) 98.0 1339.4  [M+3H]
3+ 1340.3  [M+3H]3+ 
3 26Lys-In-DOTA-GLP-1(7-36) 95.0 1266.6  [M+3H]
3+ 1265.8  [M+3H]3+ 
4 26Lys-AEEA-In-DOTA-GLP-1(7-36) 90.0 1314.9  [M+3H]
3+ 1314.6  [M+3H]3+ 
5 34Lys-In-DOTA-GLP-1(7-36) 85.3 1266.6  [M+3H]
3+ 1266.3  [M+3H]3+ 
6 34Lys-AEEA-In-DOTA-GLP-1(7-36) 97.0 1314.9  [M+3H]
3+ 1314.6  [M+3H]3+ 
7 37Lys-In-DOTA-GLP-1(7-37) 98.0 1309.3  [M+3H]
3+ 1309.5  [M+3H]3+ 
8 37Lys-AEEA-In-DOTA-GLP-1(7-37) 95.3 1357.6  [M+3H]
3+ 1357.4  [M+3H]3+ 
 
 
Table 2.3  Analysis of synthesized In-GLP-1 analogues by ESI-MS and RP HLPC. 
 
 
 
 
 
 
 
 
 
  
 
 
Scheme 2.2   Indium labeling of DOTA-GLP-1 derivatives. 
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Figure 2.5   (a) UV and (b) MS spectra obtained for compound 7 post purification.  
(a) 
(b) 
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2.3.3    In Vitro Studies 
The purified GLP-1 analogues, labeled with Indium-113/115, were evaluated 
using receptor binding assays where the displacement of [
125
I]exendin-4 by the indium 
coordinated peptide, on CHO/GLP-1R  cells, was used as a measure of the respective 
IC50 value. Figure 2.6 shows typical plots obtained from competitive displacement 
studies, in this instance for compounds 2, 7 and 8. Table 2.4 shows the obtained IC50 
values of all eight peptides. 
 
 
 
 
 
 
 
Figure 2.6    Competitive Displacement of compounds 2, 7 and 8 vs. 
125
I-exendin-4 on 
CHO/GLP-1R cells. 
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Compd IC50 (nM) cAMP 
(pmol/well) 
GLP-1 (7-37) 5 ± 3 - 
1 598 ± 45 - 
2 93 ± 7 118 ± 22 
3 970 ± 73 - 
4 2660 ± 129 - 
5 268 ± 16 - 
6 573 ± 39 - 
7 63 ± 4   74 ± 10 
8 89 ± 3 159 ± 6 
 
Table 2.4   Receptor binding and cAMP measurements for GLP-1 peptide analogues. 
The first column shows the IC50 values obtained from in vitro competitive 
displacement studies. Peptides 2, 7 and 8 were selected for cAMP studies. 
Values for cAMP were calculated as the maximal response to 10 nM 
peptide. 
 
The best results for GLP-1R binding were obtained for GLP-1 derivatives 
modified at positions 22 and 37. For the peptide with DOTA conjugated at position 37 
(7), a favorable IC50 of 63 nM was determined, while the presence of the AEEA spacer at 
position 37 (8) decreased the binding affinity of the peptide to 89 nM. This was an 
unexpected outcome as the C-terminus of the peptide is the least sterically hindered 
position along the peptide chain. Although side chain modification at position 22 has not 
been recommended in the past literature, our results indicate that, when coupled with the 
proper spacer, modification at this position has minimal negative effect on the binding 
affinity of the peptide, as indicated by 2 with an IC50 of 93 nM. Considering that the 
original residue at this position, 
22
Gly, is predicted to disrupt the helical structure of  
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GLP-1,
69-71
 it is possible that its replacement with 
22
Lys may decrease the helical 
distortion, thereby allowing the addition of the metal complex with only  minimal impact 
on its binding affinity to the GLP-1 receptor. The use of the AEEA spacer was also 
observed to have a negative impact on the binding affinity of the peptide when it was 
coupled to the Lys side chain at positions 26 and 34. This could have been caused by 
destabilization of the helical conformation of the GLP-1 derivatives as a result of steric 
hindrance or strain caused by the AEEA chain.  
 
 
2.3.4    cAMP Studies 
The production of intracellular cAMP is a measure of GLP-1R activiation.
72
 As 
GLP-1 binds to its receptor on the beta cell, intracellular Gs is activated, resulting in the 
stimulation of transmembrane adenylyl cyclases (tmACs) and elevation of cAMP 
levels.
73
 This in turn promotes glucose-dependent insulin secretion. In this study, the 
ability of peptides 2, 7, and 8 to activate GLP-1 receptors was assessed by measuring 
cAMP levels in response to 10 nM of peptide using a previously published method.
60
 As 
shown in Figure 2.7, all three peptides significantly increased cytoplasmic cAMP 
concentrations in CHO/GLP1R cells. Peptide 8 increased cAMP levels to the same extent 
as native GLP-1 (32.6-fold vs. 33.3-fold, respectively), while the response to peptide 2 
(14.4-fold) and peptide 7 (13.8-fold) was not as great (p < 0.05 compared to the fold 
increase by native GLP-1). These experiments therefore demonstrate that these analogues 
can act as GLP-1R agonists.      
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Figure 2.7  In vitro cAMP accumulation in CHO/GLP-1R  cells at basal level (white 
bars)  and following stimulation (black bars) with 10 nM of GLP-1, 2, 7, or 
8 (n = 3 for each peptide). **, p < 0.001; *, p < 0.05 (compared to basal). 
 
 
2.3.5   
111
In-Labeling  
Based on the accumulated biological data for these novel GLP-1 analogues, 
compound 8 was selected for radiolabelling with In-111 and subsequent evaluation in 
insulinoma cells. Radiolabeling was carried out in pH 5 NaOAC/HOAc buffer over 30 
minutes at 70 °C. The decay corrected radiochemical yield for the preparation of [
111
In]-8 
was 60% and the radiopurity was 98%. Monitoring of the reaction progress and 
characterization of the 
111
In-labelled peptide were carried out using RP-HPLC with 
113/115
In-labeled peptide 8 used as a non-radioactive standard for chromatographic 
comparison of retention time. Figure 2.8 shows the UV and radiochromatograms 
corresponding to this reaction. To further demonstrate the ability to radiolabel these 
* 
* 
** ** 
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DOTA-GLP-1 derivatives, the radiolabeling of 2 was also carried out under the same 
conditions as mentioned above. The radiochemical yield and purity in this case were 84% 
and 97% respectively. Figure 2.9 shows the UV and radiochromatograms corresponding 
to the preparation of [
111
In]-2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8   The HPLC (a) UV chromatogram of the standard unlabeled 8; (b) UV 
chromatogram of [
113/115
In]-8; (c) radiochromatogram of [
111
In]-8 before 
purification; and (d) radiochromatogram of [
111
In]-8 after Sep-Pak 
purification.    
 
(a) (b) 
(c) (d) 
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Figure 2.9   The HPLC (a) UV chromatogram of the standard unlabeled 2; (b) UV 
chromatogram of [
113/115
In]-2; (c) Radiochromatogram of [
111
In]-2 before 
purification; and (d) the radiochromatogram of [
111
In]-2 after Sep-Pak 
purification.    
 
 
To demonstrate that our [
111
In]-labeled peptides can be used for imaging, an in 
vitro imaging study was carried out using [
111
In]-8 and the clonal insulin-producing beta 
cell line INS-1 832/13, which expresses the GLP-1 receptor endogenously. The planar 
gamma camera image in Figure 2.10 demonstrated specific binding of the GLP-1 
analogue, as it was displaced by exendin-4. In this image, wells 1 and 2, containing the 
binding buffer and INS-1 832/13 cells, were used as a control to measure the background 
(a) (b) 
(c) (d) 
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noise. Wells 3 and 4, containing INS-1 832/13 cells and [
111
In]-8, indicated uptake of the 
hot peptide. The image of wells 5 and 6 clearly indicated displacement of the hot peptide 
by exendin-4 thus further proving that the GLP-1 derivative was taken up by GLP-1R on 
the surface of the INS-1 832/13 cells. This imaging study proved [
111
In]-8 to be a 
potential SPECT imaging agent for monitoring pancreatic beta cell mass in vivo.     
 
 
 
 
 
 
Figure 2.10    In vitro gamma camera imaging study with INS-1 832/13 cells. Wells 1 
and 2 = background control (no probe added); 3 and 4 = [
111
In]-8; 5 and     
6 = [
111
In]-8 + 10
-6
 M unlabelled exendin-4 (cold exendin-4 block). Left 
image, color contoured; right image, grey-scale. 
 
 
2.3.6   Synthesis of Gallium-GLP-1 Analogues    
Previous in vitro analysis of indium-GLP-1 analogues indicated compounds 2, 7 
and 8 to be potential candidates for in vivo SPECT imaging of pancreatic islets. 
Development of 
68
Ga-GLP-1 analogues was undertaken in order to acquire PET 
radiotracers for pancreatic islet imaging. In doing so, both naturally occurring 
69/71
Ga- 
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and radioactive 
68
Ga-labeled analogues were synthesized with compound 7. This 
analogue was selected over compound 8 owing to near identical binding affinities and 
shorter synthesis time. 
69
Ga-7 was used as an HPLC standard for the radioactive labeling 
experiments. Scheme 2.3 illustrates typical conditions for 
69/71
Ga-DOTA chelation. 
Characterization of compounds was carried out using an LCMS (ESI) as described for 
indium analogues.  
 
 
 
 
 
 
 
 
Scheme 2.3   Synthetic scheme for 
69/71
Ga-labeling of GLP-1 analogues. 
 
 
2.3.7   Gallium-68 Radiolabeling of GLP-1 analogues 
The radiometal labeling of GLP-1 compounds was carried out using an Eckert and 
Ziegler 
68
Ge/
68
Ga generator connected to a series of synthesis modules, which are 
remotely controlled by the user via a process computer (Figure 2.11). This remote access 
allows for control of specific instructions pertaining to a synthetic pathway. Scheme 2.4 
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shows a graphical representation of a program written for radiolabeling of GLP-1 
analogues. Table 2.5 lists the components and their function.  
   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11   Depiction of an Eckert and Ziegler modular lab system for 
68
Ga-
radiolabeling experiments; (a) 
68
Ge/
68
Ga generator; (b) modular lab 
automated synthesis unit. 
 
 
 
 
 
 
(a) (b) 
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Scheme 2.4   Schematic of a program written for 
68
Ga-labeling of GLP-1 analogues.  
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Component Symbol 
Vial 
 
Heater Reactor Module 
 
 
 
Three way valves 
 
 
 
Cation exchange column 
or Sep-Pak
© 
 
 
 
 
Squeeze pump 
 
 
 
Sterile filters 
 
 
 
Monitoring screens 
 
 
 
 
 
Table 2.5  Description of modular part notations used in Scheme 2.4. 
   
 
All solutions in this system, exception 0.1 N HCl in vial 1-1 which is transferred 
by a pressure pump, are transferred via pressure variance. In a typical experiment, 
gallium-68 is eluted from the generator using a squeeze pump and 3 mL of 0.1 N HCl 
(vial 1-1). This eluate, which may contain breakthrough of other impurities such as 
68
Ge, 
is then loaded onto a Phenomenix Strata-X-C 33u polymeric strong cation exchange 
column for purification. Gallium-68 is then eluted out of the cation exchange cartridge 
using 0.4 mL of 0.05 N HCl in 98% acetone (vial 1-3), and carried to the reaction vessel 
containing the solution of GLP-1 analogue. After a designated duration of heating, the 
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reaction mixture is transferred to a RP-C18 Sep-Pak
©
.
 
A 2 mL aliquot of sterile H2O (vial 
1-6) is then passed through this cartridge in order to elute impurities such as unreacted 
Ga-68. The final product is then isolated and eluted using EtOH (vial 1-7) into a clean 
sealed glass vessel (vial 1-8). A small aliquot of sterile NaCl solution (0.1-0.5 mL) can 
also be added to the final product if required for in vivo studies. A small sample of the 
final product is diluted with water (10 fold dilution) prior to analysis by RP-HPLC. The 
solvent is then evaporated on a Biotage® rapid solvent evaporator system prior to being 
assayed. The choice of solvent and quantities of GLP-1 analogues were optimized in 
order to maximize radiochemical yields (Table 2.6). Radiochemical yields were observed 
to increase proportionally with increasing peptide amounts. Considering that the use of 
larger peptide quantities results in lower specific activities, the maximum quantity of 
peptide used was set at 100 µg. Ideal radiolabeling conditions were found to be in a pH 
3.5 HEPES buffer utilizing 100 µg of peptide. Figure 2.12 shows typical chromatograms 
of labeled peptides.   
 
 
Solvent Peptide (µg) Volume (mL) DC-RCY (%) 
HEPES 10 1 0.0 
 20 1 0.8 
 50 1 12.7 
 100 1 74.8 
H2O 100 1 11.0 
NaOAc/HOAc Buffer pH 4 100 1 26 
 
 
Table 2.6   Optimization of radiometal labeling conditions for GLP-1 analogues. 
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Figure 2.12    HPLC chromatograms of GLP-1 analogue 7; (a) UV trace of 
69/71
Ga-7 
and (b) radiochromatogram of 
68
Ga-7 post purification.    
 
 
 
 
2.3.8    In Vivo Studies 
Both SPECT (
111
In-7) and PET (
68
Ga-7) candidates were studied in vivo in 
C57BL/6 mice. Figure 2.13 shows PET images obtained over 60 min after intravenous 
injection of 
68
Ga-7. Unfortunately, pancreatic islets could not be visualized owing to 
tracer accumulation in kidneys, which resulted in high background signal levels. In a 
typical study, kidney uptake was observed 4 min post injection, while clearance from 
bladder was visible 25 min post injection. Biodistribution data indicated reasonable 
uptake levels in the pancreas (Figure 2.14), thus confirming the normalization of probe 
signal from the pancreas by the kidney uptake. Lower levels of probe uptake were also 
observed in the stomach, liver, lungs and heart. In these studies, specific binding was 
confirmed by a follow-up injection of excess exendin-4 immediately after injection of the 
(a) (b) 
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radiolabeled probe. The replacement of the GLP-1 analogue indicated specific binding of 
the probe, as also evident in other organs expressing the GLP-1 receptors. Removed 
pancreata were also visualized externally using a gamma camera to further confirm the 
presence of radiolabeled probe (Figure 2.15).      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13    PET images obtained over 60 min after intravenous injection of 
68
Ga-7 
into a C57BL/6 mouse; accumulation of radiotracer in kidneys and 
bladder is observed after 4 min and 25 min respectively.  
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Figure 2.14    Biodistribution of 
68
Ga-7 in C57BL/6 mice (n=6), 4 hours post injection; 
blocking was carried out with excess Exendin-4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15   Ex-vivo gamma camera images of pancreata, hearts and stomachs obtained 
from three C57BL/6 mice 4 hours after injection of 
68
Ga-7.   
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Considering that the use of 
111
In-7 and 
68
Ga-7 was shown not to be ideal for in 
vivo pancreatic islet visualization, alternate methods of imaging the islets were sought. 
The first methodology involved further modification of the peptide backbone in order to 
reduce probe accumulation in kidneys, thus increasing signal to noise ratios. The second 
methodology utilized the radiohalogen fluorine-18, thus circumventing the need for 
radiometals and radiometal chelators. 
 
2.3.9   Modifying the GLP-1 Peptide Backbone 
High uptake of imaging probes in kidneys has been an ongoing problem in 
oncology both in terms of therapeutics as well as imaging strategies.
74, 75
 Previous reports 
by Pimm et al. and Behr et al. indicated the cause of this uptake to primarily be the 
presence of positive charged basic amino acids such as lysine and arginine.
76, 77
 As a 
result, many attempts have been made by various research groups to neutralize positive 
charges in an effort to lower the isoelectric points of compounds under study, thus 
reducing probe residence time in the kidneys. Examples of such studies include the use of 
2,3,5,6-tetrafluorophenyl glycolate or acylation to neutralize positive charges in anti-Tac 
disulfide-bonded variable region side-chain Fv fragments, which led to lower kidney 
accumulation while maintaining tumor uptake ratios.
78-80
 Another example included the 
lowering of renal accumulation of 
111
In-DTPA-conjugated peptides such as Octreotide, 
which was accomplished by increasing negative charges along the peptide backbone (eg. 
substitution of phenylalanine by aspartic acids).
81, 82
 In accordance with this theory, it was 
speculated that acylation of lysine residues and substitution of arginine residues for 
glycine, may aid in reducing charges in compound 7’s backbone. The selection of 
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residues for acylation/substitution was made not only with regards to charge, but also to 
residues reported to be essential for binding (Figure 2.4). With the above consideration, 
37
Gly was replaced with 
37
Lys (later used for DOTA conjugation), while Lysine residues 
at positions 34 and 26 were acylated. Prepared compounds were synthesized using Fmoc 
solid phase strategies. Purification and analysis of peptides was carried out as stated 
previously.      
In this study, two peptide variations were prepared with the presence of an AEEA 
linker being the only differentiating factor between the two molecules. The binding 
affinity of peptide candidates was determined using the same previously mentioned cell-
based assay methodology, incorporating CHO cells and radioiodinated exendin-4. The 
obtained IC50 values were 84.6 ± 6.8 nM for peptide containing AEEA (acyl-8) and 76.0 
± 3.9 nM for the peptide not possessing a PEG linker (acyl-7). It was noted that the 
presence of a PEG linker did not affect the binding affinity of modified peptides. As a 
result, acyl-7 was utilized further for in vivo studies. Radiochemical yield and purity of 
68
Ga-acyl-7 were 60 ± 5% and > 95% respectively. Figure 2.16 shows typical PET 
images obtained from 
68
Ga-acyl-7, clearly indicating a significant reduction in kidney 
probe accumulation. These results confirmed that a reduction in the overall positive 
charge of peptides would result in lowered probe attenuation in kidneys. Unfortunately, 
pancreatic beta cells were still not visible even after reducing kidney retention. A possible 
explanation for this observation may be mouse-model dependent GLP-1R expression. As 
a result, the expression of GLP-1R in various mouse models are currently being studied 
using both radiometal labeled 
68
Ga-7 and a dye tagged fluorescein-7 analogue. In the later 
case, FITC was used as the fluorescent tag of choice and was conjugated to 
37
Lys side 
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chain, as with DOTA. Studies to examine GLP-1R expression in vivo are currently 
ongoing.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16   PET images obtained over 60 min after intravenous injection of 
68
Ga-acyl-
7 into a C57BL/6 mouse; accumulation of radiotracer in kidneys was 
reduced while showing clearance through the bladder 5 min post injection.  
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 2.3.10  Fluorination of GLP-1  
The fluorination of large molecules such as peptides is typically carried out using 
the prosthetic group methodology, owing to limitations imposed by the use of 
nucleophilic fluoride such as high proton affinity.
83
 Among all available prosthetic 
groups, [
18
F]SFB (N-succinimidyl-4-[
18
F]fluorobenzoate) appears to be most suited for 
use with bioactive molecules and proteins, especially in terms of yields and biological 
stability of labeled compounds.
58
 The synthesis of this prosthetic group involves several 
major steps which are 1) radiofluorination of an aromatic precursor, 2) formation of 4-
[
18
F]fluorobenzoic acid, and 3) conversion of the free acid to the activated ester. There 
have been many reports on optimization of SFB synthesis with the aim of reducing 
synthesis time, improving activation step, minimizing purification steps and enhancing 
radiochemical yields.
48, 58, 84, 85
 Wester and coworkers have reported an improved 
synthesis, which satisfies the requirements for radiofluorination of biological 
compounds.
58
 Radiofluorination of GLP-1 analogues employed the use of both activated 
and non-activated [
18
F]fluorobenzoic acid analogues using solid phase and solution phase 
methodologies  
 
 
2.3.10.1  Solid Phase Approach 
In order to examine the potential of fluorinated GLP-1 analogues as PET 
radiotracers for the detection of pancreatic beta cells, synthesis of non-radioactive 
19
F-
GLP-1 analogues were carried out. Considering that previous studies on metal-chelater-
conjugated GLP-1 analogues revealed compound 7 to be a potential candidate for 
attachment of bulky groups, residue 37 was selected as a suitable position for prosthetic 
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group conjugation. For this approach, 4-fluorobenzoic acid was conjugated to GLP-1 
according to Scheme 2.5. Fluorinated product was analyzed and purified by HPLC and 
ESI-MS (Figure 2.17).      
 
 
 
 
 
 
 
 
Scheme 2.5    Synthetic scheme for 
37
Lys-(FB)-GLP-1(7-37), 9. 
 
 
A competitive cell based assay was carried out using CHO cells and 
radioiodinated exendin-4. This procedure was identical to those carried out for radiometal 
GLP-1 analogues. The binding curve obtained for this peptide Figure 2.18 (a) indicated 
an IC50 of 56 ± 6 nM, which is comparable to those obtained for promising radiometal 
chelated GLP-1 derivatives. cAMP analysis of 9 confirmed it as a GLP-1 receptor 
agonist, as indicated in Figure 2.18 (b). Receptor activation seemed to be more significant 
in the case of 9 when compared to that of 7.   
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Figure 2.17     HPLC chromatogram and ESI-MS spectrum of GLP-1 analogue 9. 
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Figures 2.18    (a) Competitive Displacement of 
37
Lys-FB GLP-1 vs. 
125
I-Exendin-4 on 
CHO/GLP-1R cells; (b) in vitro cAMP accumulation in CHO/GLP-1R 
cells at basal level (white bars) and following stimulation (black bars) 
with 10 nM of native GLP-1, 
37
Lys-In-DOTA-GLP-1(7-37) [A] and 
37
Lys-FB-GLP-1(7-37) [B].   
 
 
The solid phase synthetic route for the preparation of [
18
F]-9 is illustrated in 
Scheme 2.6. This approach required preparation of t-butyl-N,N,N-trimethylammonium 
benzoate triflate (TMABT) as the precursor for radiofluorination. Synthesis of TMABT 
started with the protection of the carboxylic acid with t-butyl in order to prevent side 
reactions in the next step. Methylation of dimethyl amine was then carried out using 
methyl trifluoromethanesulfonate (MeOTf), resulting in the formation of a quaternary 
amine suitable for nucleophilic aromatic substitution. TMABT was characterized by 
1
H-
NMR spectroscopy (Figure 2.19). Radiofluorination of this compound and subsequent 
deprotection by 2 M HCl then resulted in the formation of [
18
F]FB, which was isolated 
using a RP-Chromafix cartridge. Figure 2.20 shows a UV chromatogram of [
19
F]FB and 
radiochromatogram of purified [
18
F]FB.        
(a) (b) 
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Scheme 2.6   Synthetic scheme for the radiofluorination of GLP-1 analogues using the 
solid phase approach.  
 
 
 
 
 
 
 
 
 
 
Figure 2.19   
1
H-NMR spectrum of purified TMABT.  
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Figure 2.20     HPLC chromatograms for 4-FBA; (a) UV chromatogram of 4-[
19
F]FBA 
and (b) radiochromatogram of purified 4-[
18
F]FBA.  
 
 
 
The synthesis of [
18
F]FB, starting with TMABT, was optimized on a GE 
TRACERlab FX-N automated synthesis unit. Deprotection of [
18
F]FB was optimal with 2 
M HCl when carried out at 100 
o
C over 10 min. Decay-corrected radiochemical yields of 
[
18
F]FB were 35 ± 3% with radiochemical purities > 98%. The activation of [
18
F]FB, in 
situ (Scheme 2.6a) or in a separate step requiring further purification of [
18
F]SFB 
(Scheme 2.6b), was carried out with both HATU and TSTU. Activated [
18
F]FB was 
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obtained with the same radiochemical yield and purity as pre-activated [
18
F]FB (35 ± 3%; 
> 98%).   
Regardless of the route of activation, however, the extent of conjugation of 
18
F-
labeled prosthetic group to GLP-1 peptide analogue was extremely low (< 3%) such that 
a radiochemical yield could not be determined. However, based on HPLC integration, a 
radiochemical yield of 3% was estimated. These results did not change with temperature, 
peptide amount (ie. number of peptide-conjugated rink amide resins), or radioactivity 
amounts, indicating this approach to be unsuitable for radiofluorination of GLP-1 
analogues. It is speculated that poor coupling yields are due to low concentrations of both 
the prosthetic group as well as the peptide, in addition to steric hinderence imposed by 
the peptide backbone. As a result, a solution phase synthetic approach was considered. 
 
 
2.3.10.2  Solution Phase Methodology         
Considering results obtained from the last approach, an attempt was made to 
increase radiochemical yields by increasing peptide concentration in solution. This study 
involved the synthesis of a fully protected peptide with only one available free amine for 
reaction with [
18
F]SFB (Scheme 2.7). Solid phase Fmoc-based synthesis of GLP-1(7-37) 
was carried out on acid labile Sieber-amide resin, with Lys(Alloc)-OH at position 37. 
Palladium catalyzed removal of Alloc following by complete cleavage of the peptide 
from the resin using 5% TFA in DCM over 15 min. The peptide was then precipitated 
using t-butylmethyl ether (x2), and dried over night on a lyophilizer. Unfortunately, this 
peptide was insoluble in any solvents suitable for radiochemistry, rendering this method 
also unsuitable for radiofluorination of GLP-1 analogues. 
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Scheme 2.7   Synthetic scheme for the radiofluorination of GLP-1 analogues using the 
solution phase approach.  
 
 
2.4      Conclusion 
The objective of this project was the development of novel GLP-1 analogues for 
the targeting of GLP-1 receptors on pancreatic beta cells. To this end, we have developed 
a number of GLP-1 analogues, all shown to have high affinity for GLP-1 receptors. Three 
of the initially developed derivatives, namely compounds 2, 7 and 8, showed optimal IC50 
values indicating that positions 22 and 37 of GLP-1 are the most suitable for indium and 
gallium-DOTA conjugation. While the presence of the AEEA spacer was beneficial at 
position 22, it had a negative impact on the binding affinity of the peptide analogues at 
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positions 26, 34, and 37. The SPECT images obtained from the competitive displacement 
study between [
111
In]-7 and exendin-4 in INS-1 832/13 cells further demonstrated the 
potential of the developed probes to monitor beta cell mass. In vivo studies were carried 
out using 
111
In-7 and 
68
Ga-7 SPECT and PET probes, respectively. Preliminary data 
indicated specific uptake of the probe in the pancreas. Strong probe retention in the 
kidneys, however, prevented visualization of the pancreas by both PET and SPECT. 
Compound 7 was modified in order to reduce kidney accumulation of the radiotracer. 
This modification was successful as it resulted in lowering of kidney retention while 
maintaining similar binding affinity to GLP-1R as compound 7. Visualization of the 
pancreas, however, was still not possible. After studies with radiometal-chelator-GLP-1 
conjugates, attempts were made to synthesize fluorinated GLP-1 analogues. The 
fluorinated-GLP-1 was shown to have optimal affinity for GLP-1R while still being a 
receptor agonist. Both [
18
F]FB and activated [
18
F]SFB were successfully synthesized in 
optimal radiochemical yields for radiofluorination of GLP-1 analogues. Coupling of 
radiofluorinated prosthetic groups to 37Lys-GLP-1(7-37) was attempted using both solid 
phase and solution phase methodologies, however, these methods were found to be 
unsuitable owing to low yields and peptide insolubility. This research has resulted in the 
development of promising GLP-1 based tracers for the non-invasive imaging of 
pancreatic islets in vivo. Research on optimization of uptake and probe clearance from 
kidneys is currently ongoing.               
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CHAPTER 3.     Development of targeted Gallium-PPIX compounds 
for PET / Fluorescence dual modality imaging 
 
 
3.1    Introduction 
Molecular imaging, through non-invasive characterization and quantification of 
biological processes at cellular and sub-cellular levels, provides the potential for early 
detection and treatment evaluation of numerous disease processes. There are currently a 
number of imaging modalities available for such applications, however, the use of 
multiple modalities in conjunction has gained considerable interest as it provides more 
accurate results owing to the complementary abilities of imaging techniques. This is 
particularly important in diagnostic imaging considering that modalities with the highest 
sensitivity offer a relatively poor resolution, while those possessing high resolution suffer 
from poor sensitivity. Combining modalities provides a way to utilize the respective 
strengths from each technique, while circumventing shortcomings, leading to more 
reliable results.
1
  
Considering that each modality requires its own imaging tag (eg. radioisotopes for 
PET, dyes for fluorescence/optical imaging, contrast agents for CT/MRI) a single 
imaging probe was initially required for use with each modality of interest. Following the 
discovery of the first fused instrument (positron emission tomography/computed 
tomography, or PET/CT), however, research on multimodality imaging probes expanded 
exponentially based on the concept that while the use of a single compound for multiple 
modalities is not essential for all applications, it is certainly beneficial in terms of 
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maintaining consistent pharmacokinetics and localization in vivo. Such agents are most 
commonly prepared via attachments of all required imaging tags to one molecule. 
Another common route is using the same core compound equipped with different tags, 
but synthesized individually for imaging (eg. dye-coupled compound-A vs. radiolabeled 
compound-A). The drawback of the first methodology is the significant structural 
modifications required to make a single multimodality imaging probe, which could result 
in changes in the expected pharmacokinetics and localization behavior of the compound. 
In the latter methodology, the disadvantage lies in the structural differences between 
probes as a result of differences in the respective imaging tags.
1
 These structural 
differences, on top of altering the properties of the core molecule itself, could also lead to 
inconsistencies in imaging results obtained from different modalities. As a result, the 
development of probes that can be used for multimodality imaging without the need for 
further structural modification is desired. In this regard, using an identical compound for 
multimodality imaging would minimize discrepancies observed between modalities and, 
as well, aid in preserving the innate properties of the core molecule possessing the 
imaging tag. One class of compounds suitable for use in such applications is porphyrins. 
Porphyrins, which are naturally occurring compounds shown to play an important 
role in living organisms, and their respective derivatives have gained considerable 
interest in recent years. They have been used for numerous applications, such as in light 
harvesting,
2
 removal of reactive oxygen species (ROS),
3
 methanogenesis,
4
 electron 
transfer processes,
5
 detoxification,
6
 photodynamic therapy (PDT),
7
 and respiration.
8
 Two 
porphyrin derivatives, namely Porfimer Sodium and verteporfin are FDA-approved for 
PDT treatment of melanoma, as well as a number of cancers including those of lung, 
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digestive tract and genitourinary tract.
7, 9
 Nuclear medicine, however, most commonly 
utilizes the optical properties of porphyrins as magnetic resonance imaging (MRI) 
contrast agents.
10
  
Structurally, the porphyrin nucleus consists of four pyrrole rings connected by 
methine groups (Figure 3.1a). This ring system is very stable and exhibits aromatic 
characteristics. Functionalization of this ring leads to formation of other classes of 
porphyrins such as phthalocyanines (Figure 3.1b). Porphines typically exhibit a central 
cavity measuring approximately 4.1 Å in diameter, which is sufficient for coordination of 
a metal ion.
11
 Transition metals have previously been reported to form very stable 
complexes with porphyrin rings (eg. Zn-TPP).
12
 Examples of such complexes are 
naturally present in biological systems, such as haemoproteins (containing iron), 
chlorophylls (containing magnesium), and Vitamin B12 (containing cobalt).
13
  
 
 
 
 
 
 
Figure 3.1 Structures of (a) porphine, (b) phthalocyanine, (c) protoporphyrin IX, and 
(d) heme.   
 
One of the most abundant porphyrins is protoporphyrin (IX) (PPIX), which is 
naturally produced in the heme cycle and is the direct precursor of heme, with an iron 
core being the only differentiating factor between the two molecules (Figure 3.1c,d). 
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PPIX, having various applications, is most commonly used as a photosensitizer 
(produced by exogenous administration of aminolevulinic acid) in PDT for treatment of 
skin premalignant and malignant lesions.
14, 15
 This compound has also been shown to 
exhibit anti-bacterial and anti-malarial activity in vitro.
16, 17
 Furthermore, a recent study 
has reported the use of peptide conjugated PPIX as a potential probe for anti-cancer 
treatment.
18
 The authors reported that the attachment of a targeting moiety did not affect 
the overall efficacy of PPIX, but did significantly improve its targeting and localization 
capabilities.  
Considering the favourable fluorescence properties of porphyrins and that the 
porphine ring system exhibits a spatially appropriate central cavity for metal chelation, 
here we report the development of gallium-PPIX compounds as single molecular entities 
with potential application for both fluorescence microscopy and positron emission 
tomography (PET) imaging, without the need for further structural modification. The 
porphyrin ring, in this case, will act as both the fluorescent tag as well as the metal 
chelator, thus allowing for the same identical molecule to be used in conjunction with 
different modalities. The use of an identical molecule will preserve the characteristics of 
the core compound while reducing any inconsistencies observed in between modalities. 
The targeting entity was selected to be an RGD motif which has been well studied and 
proven to target the αvβ3 receptors typically over-expressed in a number of cancers such 
as breast,
19
 ovarian,
20, 21
 and  melanomas.
22, 23
 The radiometal of choice was gallium-68, 
which is a generator produced PET radioisotope with a 68 min half-life and 89% positron 
abundance accompanied by low photon emission (1.077 MeV, 3.2%). The use of this 
radioisotope has gained considerable interest in recent years owing to improvements in 
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the performance of commercially available 
68
Ge/
68
Ga generators.
24-26
 In this paper, we 
report the synthesis, characterization, optical analysis, radiolabeling and in vitro 
evaluation of Ga-PPIX-RGD compounds as proof of concept for the use of porphyrins as 
nuclear/fluorescence dual modality imaging agents.                
 
3.2     Experimental  
Common solvents and reagents were purchased from VWR, Fisher Scientific, or 
Sigma-Aldrich and used as received, unless stated otherwise. Sterile, deionized water was 
used in all aqueous procedures. All Fmoc protected amino acids and coupling agents, 
except Fmoc-Lys(mtt)-OH (Nova Biochem), HATU (Nova Biochem), and HBTU were 
obtained from Peptides International. Fmoc-Rink amide MBHA resin (4-(2’,4’-
dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamido-
norleucyl-4-methyl benzhydrylamine resin) was obtained from Nova Biochem. PPIX was 
obtained from Sigma-Aldrich. The hydrophilic linker AEEA was synthesized in our 
laboratory according to a previously published procedure.
27
 RP-C18 Sep-Pak SPE 
cartridges were obtained from Waters. 
68
Ge-
68
Ga generator was obtained from Eckert and 
Ziegler.   
 
3.2.1    Peptide Syntheses 
Fmoc-based solid-phase peptide synthesis was carried out manually with 0.05 
meq of 0.45 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of the protected 
amino acids. Fmoc removal, carried out with 20% piperidine in DMF (N,N-
dimethylformamide) over two cycles (10 and 20 min), was followed by amino acid 
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activation with 3 eq HBTU and 6 eq DIPEA (N,N-diisopropylethylamine) (10 min) and 
subsequent coupling over 30 and 120 min cycles.  
Coupling of AEEA to N-terminus of peptides followed the same methodology 
used in amino acid coupling, however, reaction time was increased to 16 hours. Coupling 
of PPIX was carried out using HATU, in a solution of 1:1:1 (v:v:v) DCM:DMF:DMSO 
and over 24 hours. Microcleaved samples were used to monitor reaction progress and 
peptide purity via HPLC. 
Full deprotection of synthesized peptides was accomplished using a solution of 
88% TFA (v/v), 5% H2O (v/v), 5% phenol (m/v), 2% triisopropylsilane (v/v) over 6 
hours. The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME) 
and centrifuged at 2200 rpm for 15 min. After decanting, the peptide pellet was rinsed 
with TBME, vortexed and centrifuged again. Following the removal of the supernatant, 
the peptide pellets were dissolved in water, frozen at 78 
o
C and lyophilized overnight.    
In preparing the cyclic peptide, cRGDfV, the straight sequence was initially 
synthesized using standard Fmoc-based solid phase synthesis on 0.05 meq of 0.40 
mmol/g Fmoc-Alloc(Wang resin)-OAll resin. Allyl ester deprotection was achieved using 
20 eq PhSiH3 and 0.25 eq of Pd(PPh3)4 in dry DCM. Following Fmoc removal, the chain 
was cyclized on resin using 4 eq of HATU over 4 hours. Cleavage and full deprotection 
of peptides followed the above mentioned procedures.      
 
3.2.2    Purification by RP-HPLC / ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (Sunfire
TM
 
RP-C18 column 4.6 x 150 mm, 5 μm). This system was equipped with a Waters 600 
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controller, Waters Prep degasser, and Waters MassLynx software (version 4.1). 
Employed mobile phases were 0.1% CF3CO2H in water (eluent A) and 0.1% CF3CO2H in 
CH3CN (eluent B). The linear gradient used was 30-50% of B with a flow rate of 1.5 mL 
min
-1
 over 20 min. The column eluate was monitored using a Waters 2998 Photodiode 
array detector set at 220, 254 and 400 nm. 
Peptides were purified using a reverse-phase preparative HPLC column 
(Sunfire
TM
 Prep RP-C18 OBD
TM
 column 19 x 150 mm, 5 μm) on the same system 
mentioned above. The detection method along with eluents and gradients were the same 
as those stated above, with the exception of the flow rate being set at 20 mL min
-1
. The 
collected fraction was then lyophilized to a solid and subsequently analyzed by ESI-MS 
(electrospray ionization mass spectrometry) (Waters Micromass Quattro Micro
TM
 API). 
Purity of final products was determined by analytical RP-HPLC.    
  
 
3.2.3   General procedure for synthesis of 
69/71
Ga-Labeled peptides 
In a typical reaction, 8 mg of the trimeric peptide, RGD, 3 mL of pH 5 NaOAc / 
HOAc buffer, and 5 mg of anhydrous GaCl3 (4 fold excess) were placed in a 5 mL glass 
microwave reactor vessel. The reactants were dissolved by stirring at 25 
o
C over 5 min 
before the start of the reaction, which was carried out in a microwave reactor at 70 
o
C for 
40 min. The resulting solution was then mixed with 10 mL of H2O, frozen at -78 
o
C and 
lyophilized overnight.  
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3.2.4    Optical Analyses 
UV absorption data were obtained using a Varian Cary 300 Bio UV-VIS 
spectrophotometer. Excitation and Emission data were obtained using a Photon 
Technology International QM-4 SE spectrometer equipped with double excitation and 
emission monochromators. Extinction coefficients were calculated using the serial 
dilution methodology. For this study, UV absorptions at seven different concentrations 
(highest concentration having a UV absorption maxima of 1-2) were recorded per 
compound. The slope of the resulting graph of concentration versus absorption was then 
calculated in order to obtain the value for the molar extinction coefficient. All absorption, 
excitation, and emission wavelengths were obtained in DMSO. Quantum yields were 
calculated according to previously reported comparative methods (S. Fery-Forgues, D. 
Lavabre, Journal of Chemical Education 1999, 76, 1260), using optically dilute samples 
(maximum UV absorption intensity 0.1-1) in EtOH and Rhodamine 6G as the standard.  
 
 
3.2.5    Fluorescence Microscopy using 
69/71
Ga-PPIX-AEEA-RGD (8) 
MDA-MB-435 cells were released from the tissue-culture flask using trypsin and 
seeded onto coverslips in a 12-well tissue culture plate. The cells were incubated 
overnight in DMEM containing 10% FBS at 37 
o
C with 5% CO2. Subsequently, the 
serum-containing DMEM in each well was removed and replaced with serum-free 
DMEM. Cells were incubated with 67 µM of compound 5 (control) or 8 (probe) in a 37 
o
C incubator for 1 hour Cells were then washed three times with PBS, fixed with 4% 
paraformaldehyde, and mounted with Prolong Gold antifade reagent containing DAPI 
(Invitrogen). Images were captured using the Zeiss AxioImager Z1 microscope, and the 
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average PPIX intensities in each cell was quantified using Volocity, version 4.0 
(PerkinElmer).  
 
3.2.6    Blocking of 
69/71
Ga-PPIX-AEEA-RGD with cRGDfV  
MDA-MB-435-GFP cells were released from adhesion to tissue-cultured flask 
using EDTA. Subsequently, cells were resuspended in serum free DMEM and placed in 
microcentrifuge tubes. Incubation was carried out with 67µM of 2 or 8 in suspension for 
1 h at 37 
o
C at 56 rpm. Blocking studies were conducted in the presence of 5x excess of 
cRGDfV. Cells were washed three times with PBS by centrifugation, re-seeded onto 
coverslips, cultured in DMEM and allowed to adhere. Once the cells had adhered to the 
coverslips, they were washed once with PBS, fixed with 4% formaldehyde and mounted. 
Images were captured using the Zeiss AxioImager Z1 microscope. The average PPIX 
intensities in cells were quantified using Volocity, version 4.0 (PerkinElmer). 
 
 
3.2.7    Radiolabeling to Prepare 
68
Ga-8 
To a clean glass microwave vessel was added 100 µL of PPIX analogue solution 
(1 mg/mL in pH 3.5 NaOAc / HOAc buffer). This aliquot was dissolved in 900 µL of the 
buffer (10 fold dilution to obtain final solution with µM concentrations), to which 3 mCi 
68
GaCl3 was added, freshly eluted from the Ge-68/Ga-68 generator using 3 mL of 0.1 M 
HCl. Purification and isolation of 
68
Ga was achieved using a Phenomenix Strata-X-C 33u 
polymeric strong cation exchange column (30 mg/mL), prior to transfer to the microwave 
vessel (eluent: 0.05 N HCl in Acetone). The reaction mixture was then heated in a 
microwave reactor at 120 
o
C for 45 minutes, before purification by semi-preparative 
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HPLC (Sunfire
TM
 RP-C18 column 10 x 150 mm, 5 μm) The reaction progress and 
product purity was analyzed using analytical RP-HPLC (Sunfire
TM
 RP-C18 column 4.6 x 
150 mm, 5 μm) coupled to a gamma detector. This system employed a Waters 1525 
Binary HPLC pump, Waters 2487 dual  absorbance detector, Waters In-Line degasser 
and Breeze software (version 3.30).   
 
 
3.3.      Results and Discussion 
3.3.1    Probe Design  
The primary objective of this project was to develop a single compound that could 
be used for both fluorescence and PET imaging without the need for structural 
modifications or attachment of multiple imaging tags. To this extent, the desired probe 
would employ a porphyrin ring as the inherently fluorescent metal chelator, which would 
be used in conjunction with a targeting entity. While PPIX has gained considerable 
interest owing to the versatility of its applications to various research areas, it has been 
underutilized as an imaging agent. This, in conjunction with its natural occurrence in 
biological systems, led us to select PPIX as the porphyrin ring for this study. The 
radiometal gallium-68, an efficient positron emitter used in conjunction with PET, was 
also utilized. This radiometal is produced from readily available 
68
Ge/
68
Ga generators.   
Considering that the focus of this project was to show the potential of porphyrins 
in dual modality imaging, the characteristics and behavior of the selected targeting entity 
had to be well known in order to reduce the number of variables affecting the outcome of 
this research. The tripeptide RGD was selected as the targeting entity, as it is a well 
established ligand for the αvβ3 integrin, typically over-expressed in a number of cancers 
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such as breast,
21
 ovarian,
20
 and  melanomas.
22, 23
 RGD containing compounds have been 
used in conjunction with several modalities such as PET (
68
Ga-DOTA-RGD, 
18
F-RGD 
peptides),
28, 29
 MR (Iron oxide naoparticle-RGD, Gd-DTAP-RGD)
30, 31
 and fluorescence 
imaging (quantum dot-RGD).
32
 As a result, the RGD moiety was selected as the preferred 
targeting entity for the αvβ3 receptors. 
A major drawback in using porphyrin derivatives is the extreme hydrophobic 
nature of these compounds, which raises numerous challenges in their handling due to 
significantly reduced product solubility. As a result, a short polyethyleneglycol (PEG) 
chain was added between PPIX and RGD in order to enhance the overall solubility of the 
compound. The PEG linker of choice was Fmoc-AEEA, which was synthesized 
according to a previously published procedure.
27
 The overall design of the probe is shown 
in Figure 3.2. 
     
 
              
 
 
 
 
 
 
 
Figure 3.2 Structure of the proposed imaging probe.    
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3.3.2    Synthesis of 
69/71
Ga-PPIX analogues 
RGD peptides were synthesized manually using standard Fmoc-SPPS methods. 
An example of this methodology is illustrated in Scheme 3.1. Typical yields, obtained 
post HPLC-purification, were 60-70% with purities over 95%. It is important to note that 
the formation of both PPIX-AEEA-RGD and PPIX-(AEEA-RGD)2 analogues was 
observed at the end of the reaction. This was beneficial as this project initially aimed at 
studying both of these compounds in order to examine any advantages associated with 
having multiple targeting moieties present on the imaging probe. Use of PPIX was also 
advantageous towards simplifying this synthetic route due to the presence of two free 
carboxylic acids available for acylation. A drawback of this protocol, however, was the 
lack of regioselectivity involved with the acylation of PPIX, as two regioisomers could be 
produced. Although these isomers cannot be separated due to their very similar physical 
characteristics, their presence is not likely to alter the overall localization or fluorescence 
of PPIX conjugates in cancer cells.
18
 As a result, other porphyrin rings could be 
employed if a single specific regioisomer is desired (eg. in drug development). 
Considering that this project also aimed to study the effects of peptide and linker addition 
on the optical properties of PPIX, eight PPIX analogues were synthesized containing one 
or more linker/peptide moieties in addition to their gallium-labeled counterparts. The 
purity and ESI-MS characterization of the prepared compounds are given in Table 3.1.         
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Scheme 3.1 Synthetic pathway for the preparation of PPIX-AEEA-RGD analogues.   
 
 
 
# Compound Purity 
(%) 
Calculated m/z Observed m/z 
2 PPIX-AEEA 97.0 709.4   [M+H]
+
  709.2   [M+H]
+
 
3 PPIX-(AEEA)2 96.0 853.5   [M+H]
+
  853.4   [M+H]
+
 
4 PPIX-AEEA-RGD 95.0 1037.5 [M+H]
+
  1037.7 [M+H]
+
 
5 PPIX-(AEEA-RGD)2 97.0 755.7   [M+2H]
2+
  756.6   [M+2H]
2+
 
6 
69/71
Ga-PPIX-AEEA 98.0 775.3   [M+H]
+
  775.4   [M+H]
+
 
7 
69/71
Ga-PPIX-(AEEA)2 97.0 919.3   [M+H]
+
  919.4   [M+H]
+
 
8 
69/71
Ga-PPIX-AEEA-RGD 98.0 1104.4 [M+H]
+
  1104.9 [M+H]
+
 
9 
69/71
Ga-PPIX-(AEEA-RGD)2 98.0 790.3   [M+H+Na]
2+
  790.3   [M+H+Na]
2+
 
 
 
Table 3.1 Analysis of synthesized PPIX-RGD analogues by RP-HLPC and ESI-MS. 
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Chelation of naturally occurring gallium (Scheme 3.2) was carried out in order to 
prepare non-radioactive compounds for in vitro imaging, optical analysis, preparation of 
HPLC standards and determination of radiolabeling conditions, while preventing 
unnecessary radiation exposure. Chelation of a metal ion to the porphyrin central cavity 
requires high reaction temperatures. Metal chelation reactions of porphyrins using 
conventional heating methods have been reported to require very long reaction times, 
often continuing overnight at elevated temperatures.
33
 Microwave reactors, however, 
have been reported to facilitate metal chelation reactions leading to significantly reduced 
reaction times.
34-37
 As a result, this study employed the use of a microwave reactor in 
order to facilitate reaction rates. In addition, a pH 3.5 sodium acetate/acetic acid buffer 
was employed in order to minimize formation of insoluble gallium hydrolysis products.
38
 
It was noted that chelation efficiencies improved with increasing reaction time, reaching 
95% completion after 40 minutes of heating at 75
o
C. Products were purified using 
preparative HPLC and subsequently analyzed using ESI-MS. 
  
 
 
 
 
 
Scheme 3.2 Synthetic scheme for the preparation of 
69/71
Ga-PPIX-AEEA-RGD.   
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3.3.3    Optical Analysis 
Optical properties of compounds 2-9 was studied and compared to the parent 
compound PPIX (1) in order to evaluate the potential for fluorescence microscopy. The 
observed excitation and emission wavelengths (Figure 3.3) are reported in Table 3.2. 
Both peptide/linker conjugation as well as gallium-chelation caused a blue shift in the 
excitation wavelengths from 467 nm for native PPIX to 429-437 nm for gallium 
coordinated 6-9. A similar trend was observed for emission maxima with an approximate 
wavelength decrease of 50 nm from PPIX to the gallium congener. Maximum absorbance 
wavelengths did not change significantly ( ~ 7 nm post gallium chelation), while 
extinction coefficients were affected by gallium chelation with a greater than two-fold 
increase. The quantum yields were consistent pre and post gallium chelation, indicating 
that metal-dependent fluorescence-quenching is minimal in these compounds. This is a 
particularly important observation since a number of other metals (eg. Mg, Sn, Zn) were 
recently reported to quench the fluorescence of PPIX with quantum yields dropping 
below 5%,
39
 while the quantum yields for 6-9 are maintained above 30% (Table 3.2). 
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Figure 3.3   (a) absorption (blue) / emission (orange) data obtained for 8; (b) photo of 
visible emission of 1-9 under 365 nm light. 
 
# Compound  ex 
(nm) 
em 
(nm) 
abs 
(nm) 
ε  
(M
-1
) 
Φ 
1 PPIX  467 638 406 17377 0.37 
2 PPIX-AEEA  467 638 407 11415 0.34 
3 PPIX-(AEEA)2  467 635 407 12554 0.32 
4 PPIX-AEEA-RGD  441 633 407 15120 0.42 
5 PPIX-(AEEA-RGD)2  446 632 407 11559 0.31 
6 
69/71
Ga-PPIX-AEEA 414 585 414 42550 0.49 
7 
69/71
Ga-PPIX-(AEEA)2 420 584 415 41599 0.33 
8 
69/71
Ga-PPIX-AEEA-RGD  437 593 414 32226 0.42 
9 
69/71
Ga-PPIX-(AEEA-RGD)2  429 585 413 47661 0.49 
 
Table 3.2 Photophysical data for PPIX derivatives 1-9: excitation, emission, 
absorbance maxima wavelengths, extinction coefficients and quantum 
yields (experimental details provided in Supplementary Information). 
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3.3.4     In Vitro Imaging 
In order to demonstrate the potential of these analogues for fluorescence imaging, 
8 was evaluated in vitro using the MDA-MB-435 cancer cell line, which over-expresses 
the αvβ3 integrin. For this study compound 6 was selected as the negative control, which 
is identical to compound 8 with the exception of lacking the RGD targeting moiety. After 
incubation of 8 with cells, and subsequent washing, confocal microscopy images were 
obtained. The cellular uptake of compound 8 was statistically significant and visually 
pronounced, while the signal from the negative control was nominal, with approximately 
a 4:1 signal ratio between 8 and 6 (Figure 3.4). Compounds 7 and 9 were very 
hydrophobic and therefore were not evaluated in vitro. In order to confirm specific uptake 
of 8 to MDA-MB-435 cells, a blocking experiment was carried out using a cyclic RGD 
pentapeptide, cRGDfV, which has high affinity for the αvβ3 integrin.
40
 The statistically 
significant displacement of 8 by the blocking moiety demonstrated specific binding of the 
probe to the MDA-MB-435 cell line, therefore confirming the specificity of 8 for the 
integrin target. 
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Figure 3.4  Fluorescence microscopy of 8 in GFP-expressing MDA-MB-435 cells: (a) 
uptake of 8 indicated in yellow (left panel), GFP-expressing cells in green 
and DAPI stained nuclei in blue (right panel); (b) uptake of negative control 
6 in yellow (left panel); (c) cells with no treatment (left panel); (d) quantified 
data for uptake of targeted 8 vs non-targeted 6; (e) quantified data for uptake 
of 8 vs uptake of 8 in cells treated simultaneously with cRGDfV peptide 
(block). 
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3.3.5    
68
Ga-Labeling  
Radiolabeling of compound 7 with gallium-68 was carried out in a microwave 
reactor according to Scheme 3.3. Optimal reaction conditions were found to employ a pH 
4.5 HOAc/H2O solution with a 45 minute reaction time at 120 
o
C. The decay corrected 
radiochemical yields were typically 30-35% with radiochemical purity >98%. In theory, 
chelation efficiency of porphyrins could be improved with increasing reaction periods 
and temperatures. In this case, however, peptide instability and hydrolysis of free 
gallium-68 were observed with further increment in both variables. Monitoring of 
reaction progress as well as characterization of the radiolabeled products was carried out 
using RP-HPLC with utilization of compound 7 as the non-radioactive standard. The 
desired 
68
Ga-labeled product was identified by chromatographic comparison of retention 
times between radiolabeled and non-radioactive compounds. Figure 3.4 shows 
representative UV and radiochromatograms corresponding to this reaction. It is important 
to note that there is a retention time difference of 1.5 minutes between starting material 
PPIX-AEEA-RGD and final product 
68
Ga-PPIX-AEEA-RGD, thus facilitating their 
separation by RP-HPLC at the end of reaction. It is also worth noting that the final 
product can also be purified using a RP-C18 Sep-pak®. In summary, this study further 
confirms the ability of PPIX to act as a gallium-68 radiometal chelator, as well as the 
potential of this probe as a PET imaging agent.   
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Scheme 3.3 Radiolabeling scheme for compound 8.   
 
 
 
 
 
 
 
 
 
 
Figure 3.5   The HPLC (a) UV chromatogram of the standard unlabeled 4; (b) UV 
chromatogram of [
69/71
Ga]-8; (c) radiochromatogram of the reaction 
mixture pre-purification; and (d) radiochromatogram of [
68
Ga]-8 post 
purification.    
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3.4       Conclusion  
The aim of this study was to develop porphyrin-based analogues as dual modality 
fluorescence/PET imaging agents without requiring the attachment of multiple imaging 
tags to the molecule. To that end, we have developed derivatives of PPIX-RGD which 
can be used for both fluorescence and PET imaging without the need for modification. 
Metal chelation conditions were optimized for gallium labeling (both radioactive and 
naturally occurring) and the coordination with gallium produced strongly fluorescent 
molecules with quantum yields of >30%. The versatility of this approach permits the use 
of different targeting entities based on the desired biological target, while allowing for 
progression from in vitro evaluation (fluorescence) through to in vivo imaging (PET), 
with consistent imaging results between modalities. 
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CHAPTER 4.     A cell-based approach for OBOC combinatorial 
library screening against cell surface receptors 
 
 
4.1   Introduction 
An initial step in the development of drugs and therapeutic agents is the 
identification of compounds that bind the biological target of interest such as enzymes, or 
surface receptors. After identification of the molecule of interest, many analogues are still 
synthesized in order to optimize biological variables such as activity and lipophilicity. 
Discovery and optimization of potential candidates typically involves the evaluation of a 
large number of compounds, making this approach an extremely labor intensive and 
time-consuming process. In order to facilitate these demands, various chemical and 
biological methods have been developed for the generation of combinatorial libraries and 
the subsequent screening of compounds therein against biological targets of interest in 
order to identify high-affinity ligands.
1
 Considered one of the most important recent 
advances in medicinal chemistry, this approach is currently utilized in major 
pharmaceuticals companies as a powerful tool for the discovery of potential agents for 
diagnostic and therapeutic applications.
2
  
In general, all library-based methods consist of three key steps which are 1) 
preparation of a combinatorial library, 2) screening of compounds against biological 
targets, and 3) structure determination of potential imaging/drug candidates. Libraries 
may contain various classes of compounds including, peptides,
3
 oligonucleotides,
4
 
proteins,
5
 synthetic oligomers,
6
 small molecules,
1
 and oligosaccharides.
2, 7, 8
 Libraries can 
be prepared via biological/biochemical or synthetic approaches. For instance, peptides 
could be either chemically synthesized or biologically expressed using a phage display 
158 
  
approach.
9
 Compounds requiring chemical syntheses are commonly prepared via a solid 
phase methodology. Here, the solid support acts as an insoluble and inert material for the 
covalent attachment of compounds, thus facilitating isolation and identification 
processes.
1
  
There are currently four major but distinct combinatorial library methods. The 
first approach is a biological library method such as phase display.
10
 Here, 
peptides/proteins are expressed biologically using genetically modified plasmids. These 
compounds are then screened for binding against DNA or protein of interest. A second 
approach involves spatially addressable libraries such as the multipin system, which 
involves the use of separate polyethylene pins as reaction media for synthesis of 
individual compounds.
11
 A third technique involves synthetic solution library methods 
such as affinity capillary electrophoresis (ACE).
12
 Here, a competitive binding assay is 
used in conjunction with ACE, to identify high-binding ligands for the biological target 
of interest. The last method is based on the one-bead-one-compound (OBOC) 
combinatorial library approach. In this method a large number of variable peptide 
sequences are synthesized on solid support in a spatially independent fashion.
2, 13
 
Sequence determination of peptide candidates from this library is then carried out using 
mass spectrometry techniques such as MALDI-TOF/TOF.
14
 There have also been reports 
on variations of this approach. An example of this variation entailed the use of peptide 
fragments, instead of single amino acids, in the split synthesis of larger peptides.
15
 
Considering that there are cons and pros associated with each approach mentioned above, 
selection of a suitable method is case-specific and relies heavily on the target, assay 
system and available resources. The work discussed in this dissertation utilizes an OBOC 
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approach, in conjunction with deconvolution methods, for screening of a peptide-based 
library.   
OBOC libraries have been successfully applied to peptides, oligomers and small 
organic molecules.
2
 Libraries employing this approach are typically prepared on resin via 
a split synthesis approach, which involves mixing and splitting resins following each 
amino acid coupling (Scheme 4.1).
16
 Products of this process would consist of a vast 
number of beads, each containing only one peptide sequence, with various amino acid 
sequences. For instance, a library of octameric peptides prepared from a selection of 20 
natural amino acids would consist of over 25 billion sequences of peptides. For this 
application, beaded polymers have to fulfill certain structural characteristics of which 
size, substitution homogeneity (i.e. number of available functional groups on the bead 
surface), resistance to cluster formation, and swelling abilities are most important. 
Examples of common beads used for such applications include Tentagel 
(polyoxyethylene-grafted polystyrene),
17
 PEG-PS resin,
18
 and ArgoGel.
19
 TentaGel 
beads, which are PEG-PS based and typically utilized in bead binding assays, exhibit 
polyoxyethylene chains between the solid support and synthesized compounds thereby 
reducing steric effects imposed by the bead. PEG-PS beads possess polyoxyethylene 
chains as means to modify the polymer properties as they make up 70% of the resin 
weight. ArgoGel resins have higher substitution levels, which is made possible by 
branching of polyoxyethylene groups at the attachment point to the polystyrene core 
(Figure 4.1).    
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Scheme 4.1     Synthetic pathway for a randomized combinatorial library.  
 
 
 
 
 
 
 
 
 
Figure 4.1.    General structures of (a) Tentagel and PEG-PS and (b) ArgoGel-MB-NH2 
resins. 
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The binding of bead-bound compounds to biological targets can be visualized via 
direct or indirect routes. The direct route involves, for instance, the visualization of a 
colored target such as a dye
20
 or a larger target such as a cell.
21
 Indirect visualization, on 
the other hand, involves the use of reporter groups such as enzymes, radionuclides, or 
fluorescent probes.
2
 In both screening processes, non-specific binding should be 
minimized in order to increase signal to noise ratios. Binding to an undesirable site can 
usually be eliminated, or at least significantly minimized, by using a high ionic strength 
buffer (eg. 0.3-0.4 M NaCl), with non-ionic detergent (eg. 0.1% Triton X-100) and 
blocking proteins (eg. bovine serum albumin).
2
   
Various screening methods for OBOC combinatorial libraries have been reported. 
A common route of identifying lead compounds is a colorimetric-based enzyme-linked 
on-bead assay.
22
 In this approach, peptide-conjugated beads are enzymatically 
phosphorylated and subsequently treated with a dye. Lead compounds which would be on 
colored beads are then isolated using selective antibodies. Figure 4.2a illustrates typical 
appearance of a cell batch in this assay with positive beads appearing darker. Beads could 
also vary in color pending on the extent of binding. Beads exhibiting ligands with a 
higher biological affinity appear darker (Figure 4.2b). Another method of screening is a 
whole-cell on-bead binding assay.
23
 Direct visualization of cells (6-10 µm in diameter) 
binding to ligand-conjugated beads (90-120 µm) is carried out under a microscope. This 
method was previously utilized in identifying peptides that bind integrins on prostate 
cancer cell lines. Figure 4.2c illustrates a typical example of this procedure for the 
identification of compounds binding cell surface receptors. In theory, the OBOC library 
approach can also be applied to viral particles, bacteria or yeast given the appropriate use 
162 
  
of a reporter/signaling group. Table 4.1 lists some biological targets for which OBOC 
libraries were utilized in finding high-affinity ligands. 
 
 
 
 
Figure 4.2  (a) Depiction of an OBOC assay with hit beads appearing dark, (b) a 
collection of beads with varying color intensity as reflected by ligand 
binding, darker colored beads exhibit higher affinity, (c) depiction of a hit 
bead in a whole cell on-bead binding assay, showing attachment of 
inherently fluorescent cells to the surface of the bead. 
 
 
While the OBOC library approach allows for the ability to test a large number of 
compounds simultaneously but individually, owing to the spatially separable nature of 
compounds on beads, it would still be advantageous to combine multiple approaches in 
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order to solve specific problems or improve overall screening abilities. Here, we report a 
novel and rapid on-bead cell-based method of screening peptide libraries.       
 
Target 
Monoclonal antibodies  
Lymphoma cells 
Streptavidin/avidin 
Thrombin 
SH3 domain 
Dopamine D2 receptors  
Organic dyes 
Prostate cancer surface integrins 
Protease substrate 
Protease inhibitor 
Tyrosine kinase  
G-protein coupled receptors 
Anticancer agents 
MSH 
Carbonic anhydrase  
 
 
Table 4.1     A list of biological targets for which OBOC combinatorial library assays 
were employed in identification of high affinity ligands.
2, 13, 20, 21, 23-34
  
 
 
4.2       Experimental  
4.2.1.   Materials  
Common solvents and reagents were purchased from VWR, Fisher Scientific, or 
Sigma–Aldrich and used as received, unless stated otherwise. Sterile, deionized water 
was used in all aqueous procedures. Fmoc protected amino acids, HBTU, and Tentagel S 
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NH2 resin were obtained from Peptides International. N-Fmoc-3-amino-3-(2-nitrophenyl) 
propionic acid (Fmoc-ANP) was obtained from Chem-Impex International, Inc.  
 
4.2.2.  Peptide Synthesis  
Fmoc-based solid-phase peptide synthesis was carried out using an APEX 396 
autosynthesizer (AAPPTec, Louisville) with 0.05 meq of 0.26 mmol/g Tentagel S NH2 
(90 µm, 0.27 mmol/g) resin. 1.5 meq of Fmoc-ANP and subsequently, a three-fold excess 
of the protected amino acids were used in coupling reactions. Fmoc removal was carried 
out using a solution of 20% piperidine in DMF (N,N-dimethylformamide) over two 
cycles (10 and 20 min). Amino acid activation was carried out with 3 eq of HBTU and 6 
eq of DIPEA (N,N-diisopropylethylamine), which was followed by amino acid coupling 
over 30 and 120 min cycles. Deprotection of peptide side chains was accomplished using 
a solution of 88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane 
(v/v) over 6 h.  
Cleavage of peptides from Tentagel beads was carried out using UV irradiation. 
All care was taken to prevent light exposure to synthesized peptides prior to ANP-linker 
cleavage. For this reaction, approximately 1-3 peptide conjugated Tentagel beads were 
placed in 200 µL of MilliQ water in an open-top 384 well polypropylene plate. UV 
irradiation was carried out using a 365 nm UV lamp (UV Products, Upland, CA, model 
EL25, 8 mWcm
−2
) over 2.5 hours. Water was added periodically in order to prevent wells 
from drying, thus reducing possible peptide decomposition. The resulting peptide-
containing solution was then used for MALDI-TOF/TOF analysis.  
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4.2.3.   On-bead Cell-based Assay for Screening Peptide Library 
The αvβ3 integrin-expressing MDA-MB-435 cells were transfected with green 
fluorescent protein. Approximately 1000 beads containing each peptide were equilibrated 
with serum-free DMEM in a 12-well plate. MDA 435 cells were detached from the flask 
by EDTA and resuspended in serum-free DMEM. Approximately 200000 cells were 
added to each well, containing peptide-conjugated beads, and subsequently placed in a 
shaking incubator (50 rpm) for 1 hour at 37
o
C. Beads were then washed twice with PBS, 
and imaged under the Olympus IX70 inverted fluorescent microscope. Cells were fixed 
onto beads with 3% formaldehyde for 5 minutes at room temperature, and washed twice 
with PBS.  
 
4.2.4.   High throughput Screening 
Beads from each well were inserted into the COPAS
TM
 large particle flow 
cytometer (Union Biometrica), and sorted into a 96 well plate. The fluorescence intensity 
threshold for sorting was defined using non-functionalized Tentagel beads. Beads with 
fluorescent intensity higher than the set threshold were sorted into the 96-well plate. 
Sorted beads were imaged using an Olympus IX70 inverted fluorescent microscope. Post 
imaging, beads were then treated rigorously with ethanol to remove bound cells. Rinsing 
with water was carried out several times prior to MALDI-TOF analysis.  
 
4.2.5.  MALDI-TOF MS/MS Analysis 
In a typical experiment, the exact molecular ion mass [M+H]
+
 of a peptide was 
determined using MS analysis. MS/MS spectra were subsequently recorded for the 
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desired molecular ion peak, previously observed by MS. This was then followed by 
manual deconvolution of all peptide sequences. 
 
4.3       Results and Discussion 
The aim of this project was the development of an improved procedure for the 
screening of peptide libraries. To that end, we have devised a methodology wherein 
peptide-conjugated Tentagel beads are screened against cell surface receptors and 
subsequently sorted, while still attached to cells, based on fluorescence intensity. To the 
best of our knowledge, this is the first example of a screening procedure where cells that 
are attached to peptide-conjugated beads are directly monitored and screened for lead 
compounds in an automated fashion. This automated procedure is especially significant 
in reducing time-intensive labor associated with the manual isolation of beads coated 
with high-affinity or hit ligands (hit beads). Isolation of hit compounds using magnetic 
particles was recently reported,
35
 however, this approach necessitates conjugation of 
magnetic particles (eg. quantum dots), and multiple antibodies in order to find ligands 
with optimal binding affinity. Addition of more variables in the screening process (i.e. 
multiple large entities), may reduce the overall efficiency of screening as a result of 
enhanced non-specific uptake. Furthermore, collection of hit beads with a magnet often 
results in entrapment of false beads containing non-targeting compounds, thus requiring a 
second screening process where beads are either manually inspected or put through a 
flow cytometer for secondary isolation.
36
 As a result, having an automated procedure, 
which only necessitates the presence of peptide-conjugated beads and cells of interest, 
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would be greatly beneficial as it provides a more efficient (i.e. less labor-intensive, more 
time efficient, more consistent bead isolation) route for finding potential hit compounds.  
As a proof of concept for this procedure a small library of seven heptameric 
peptides (Table 4.2) were synthesized via Fmoc solid phase methodology, on 90 µm 
Tentagel beads, which have been previously reported to be efficient solid support 
candidates for preparation of combinatorial libraries. The well studied αvβ3 expressing 
cell-line, MDA-MB-435, was utilized in this work. In addition, the pentameric peptide 
GRGDS was incorporated in the sequence of all prepared peptides as it has been 
previously reported to bind αvβ3 integrins.
37-41
 The last two amino acids of the prepared 
peptides were selected at random in order to more closely mimic a combinatorial library. 
A photolabile linker (ANP) was placed between Tentagel beads and the corresponding 
conjugated peptides in order to facilitate peptide removal post screening. Employing this 
linker allows for complete removal of all acid-labile amino acid side-chain protecting 
groups without removing peptides. This is necessitated by the screening process, which 
requires the use of fully deprotected, but still resin-bound, peptides. Figure 4.3 illustrates 
the general design of the studied peptides.   
A COPAS
TM
 Biosorter flow cytometer (Figure 4.4) was used as means for high-
speed automated analysis and sorting of cell-bead conjugates. This system was initially 
designed to analyze and sort living multicellular organisms based fluorescent protein 
expression, with rates of up to 100 organisms per second. This work employed the 
capabilities of this instrument for sorting and isolation of hit peptides based on the overall 
fluorescence intensity of cell-bead conjugates. The inherent green fluorescence of 
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Tentagel beads, in this case, did not interfere with the isolation of beads as the signals 
obtained from adhesion of GFP-expressing cells was much more pronounced.   
     
  
 
 
 
 
 
Table 4.2    List of prepared peptide sequences for cell-based screening assay.  
 
 
 
 
 
 
 
 
Figure 4.3    Illustrates overall design of prepared peptides.  
 
# Sequence 
1 GRGDSPS 
2 GRGDSYT 
3 GRGDSWK 
4 GRGDSHL 
5 GRGDSVP 
6 GRGDSTW 
7 GRGDSFA 
8 HMYFLLGH 
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Figure 4.4   An illustration of a COPAS
TM
 Biosorter showing the mechanism of 
detection and isolation of fluorescent samples.
42
      
 
In a typical experiment, GFP-expressing cells were incubated with each peptide 
from the prepared library. After rinsing with PBS medium, cells were fixed onto beads 
using formaldehyde, which ensured the binding of cells to the surface of beads. This step 
was confirmed to be a necessity as untreated cells were observed to dissociate from beads 
during the sorting process. Cell-bound beads where then loaded onto the COPAS
TM
 flow 
cytometer, which isolated hit beads based on fluorescence intensity. Peptides were then 
rinsed and cleaved from the resin prior to analysis by MALDI-TOF. Figure 4.5 shows 
images of compound 1 taken with an Olympus IX70 inverted fluorescent microscope. 
Images indicate a reduction of adhered cells post rinsing, which is due to the clearance of 
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non-specific cell uptake. Images of beads post rinsing and sorting were comparable. 
Using the same methodology, cell sorting, isolation and imaging for other peptide 
candidates in the library was carried out (Figure 4.6). As can be seen, peptides 1, 3, 4  
and 7 exhibited highest levels of binding. Peptide 8 was used as a negative control 
because of its lack of affinity for αvβ3 integrins. This was further confirmed by the 
COPAS
TM
 sorter which did not isolate any 8-bound beads.              
 
 
 
 
 
 
Figure 4.5     Images of MDA-MB-435 cells adhered to Tentagel beads containing 1 
pre-wash (left), post-wash (middle) and post-sorting (right).   
 
 
Considering that this is the first-reported fully automated cell-based screening 
assay, it was deemed necessary to confirm the ability to identify hit peptides both pre and 
post sorting. This was especially important in ruling out fragmentation prevention by 
residual formaldehyde that could be present after cell sorting. For this reason, MALDI-
TOF/TOF analysis of standard peptides and those post sorting were carried out. In the 
former case, synthesized peptides on Tentagel beads were fully deprotected using a TFA 
cleavage cocktail containing scavengers. Under a light inverted microscope, 1-3 beads 
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Figure 4.6 Images of MDA-MB-435 cells adhered to peptide-conjugated tentagel beads 
pre-wash (left columns), post-wash (middle columns) and post-sorting (right 
columns).   
 
were separated and placed, with 200 µL of MilliQ water, into one well of an open-top 
384 well polypropylene plate. Removal of peptides from the resin was then carried out by 
exposure to a 365 nm UV light over 2.5 hours. Water was added periodically in order to 
prevent wells from drying, thus reducing possible peptide decomposition. The resulting 
peptide-containing solution was then used for MALDI-TOF/TOF analysis. As mentioned 
earlier, peptide-conjugated Tentagel beads were fully deprotected, but still bound to 
Tentagel beads, prior to analysis by the COPAS sorter. After cell sorting, removal of 
peptides from hit beads was accomplished using the same procedures as those used for 
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standard untreated beads. All peptide solutions were then analyzed by MALDI-
TOF/TOF. In a typical experiment, the exact molecular ion mass [M+H]
+
 of a peptide is 
determined using MALDI-TOF analysis. MS/MS spectra are subsequently recorded for 
the desired molecular ion peak, previously observed by MS. This was then followed by 
manual deconvolution of all peptide sequences in this work. Fragments were calculated 
and reported according to published procedures.
43
 Figure 4.7 illustrates commonly 
observed peptide fragmentation patterns. Missing fragments can be calculated only if the 
complementary fragment is observed. Figure 4.8 shows the MS/MS spectrum obtained 
for untreated 1, which was used as a standard point of comparison to MS/MS spectra 
obtained post cell sorting (Figure 4.9). As it can be seen, differences between MS/MS 
spectra of pre- and post-sorted peptides are minimal, indicating that treatment and 
handling of cell-peptide-bead conjugates in this methodology does not negatively impact 
the peptides. In addition, successful sequencing of peptide candidates confirms the 
consistency in sequencing ability pre- and post-sorting (Tables 4.3 and 4.4). Tables 4.5-
4.10 list calculated and observed fragmentation patterns for compounds.   
In certain cases N-terminal glycine was not observed and could not be calculated 
by complementarity. In these situations the combined molecular weights of the last two 
N-terminal residues was calculated to be that of Gly and Arg. The order of the two 
residues was determined by considering possible side chain fragmentation of Arg 
(Scheme 4.2)
44
 as well as overall molecular weights of residues. Assuming the N-
terminal peptide sequence order, RG, would indicate that the molecular weight 
corresponding to arginine should still be observable after glycine fragmentation. 
Assuming the N-terminal peptide sequence GR, on the other hand, would indicate that 
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upon arginine fragmentation, the remaining molecular weight (i.e. glycine), would be too 
low to be definitively observed, as in all cases in this study. Given the lack of evidence 
for the presence of arginine or any side chain fragmented derivatives, it was concluded 
that the likely order of sequence for the last two N-terminal residues was in fact GR.           
          
    
 
 
 
Figure 4.7      Common peptide fragmentation patterns and the corresponding fragment 
notations.
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Absence of these fragments was especially apparent for peptides 3 and 6 where 
even the standard un-treated samples exhibited this pattern (Tables 4.6 and 4.9). Peptides 
2 and 7, on the other hand, only displayed this pattern for treated samples, as sequences 
for untreated peptides were completely deconvoluted (Tables 4.5 and 4.10). The cause of 
this incomplete fragmentation was initially postulated to result from trace amounts of 
formaldehyde, previously used in fixing cells, in the final peptide solution used for 
MALDI-TOF/TOF analysis. However, fragmentation patterns observed for peptide 4 
disproved this hypothesis as the sequence of treated samples, unlike those of standards, 
was completely deconvoluted. This pattern, therefore, may have simply been a result of 
the difficult fragmentation of argenine residues.           
174 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8    MS/MS spectrum of GRGDSPS peptide standard; 
a
 denotes fragments calculated by complementarity.  
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Figure 4.9    MS/MS spectrum of GRGDSPS peptide post sorting; 
a
 denotes fragments calculated by complementarity.  
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Fragment  Expected  Found  Residue Lost 
b1  58.03  58.11
a
  Arg 
b2  214.13  214.12  Gly 
b3  271.15  271.14  Asp 
b4  386.18  386.17  Ser 
b5  473.21  473.19  Pro 
b6 - amine  553.23  553.19  Ser 
y1  105.06  105.12
a
  Pro 
y2  202.12  202.12  Ser 
y3  289.15  289.15  Asp 
y4  404.18  404.17  Gly 
y5  461.20  461.21
a
  Arg 
y6 - amine  600.27  600.23  Gly 
 
Table 4.3 Calculated and observed fragmentation patterns for untreated GRGDSPS 
peptide. 
a 
Fragments were calculated by complementarity.   
 
 
Fragment  Expected  Found  Residue Lost 
b1  58.05  58.05
a
  Arg 
b2  214.15  214.13  Gly 
b3  271.17  271.14  Asp 
b4  386.20  386.15  Ser 
b5  473.23  473.17  Pro 
b6 - amine  553.25  553.2  Ser 
y1  105.08  105.12
a
  Pro 
y2  202.14  202.11  Ser 
y3  289.17  289.14  Asp 
y4  404.20  404.17  Gly 
y5 - amine  445.20  445.15  Arg 
y6  617.32  617.30  Gly 
 
Table 4.4    Calculated and observed fragmentation patterns for GRGDSPS peptide post 
sorting. 
a 
Fragments were calculated by complementarity.  
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Table 4.5  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSYT-NH2 peptide (2). 
a 
Fragments were calculated by 
complementarity.   
 
Fragment Expected Found Residue 
b1 58.03 N/A -  
b2 214.13 214.12 Gly 
b3 271.15 271.15 Asp 
b4 386.18 386.16 Ser 
b5 473.21 473.17 Trp 
b6 659.29 659.74 Lys 
z1 129.10 129.10 Trp 
z2 315.18 315.15 Ser 
z3 402.21 402.23
a Asp 
z4 517.24 517.24
a Gly 
y5 589.28 589.17 Arg 
z6 746.38 N/A - 
 
Table 4.6  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSWK-NH2 peptide (3). 
a 
Fragments were calculated by 
complementarity.   
Fragment Expected Found Residue 
b1 58.05 58.08
a Arg 
b2 214.15 214.13 Gly 
c3 289.20 289.16 Asp 
b4 386.19 386.17 Ser 
b5 - amine 456.20 456.16 Tyr 
c6 654.33 654.24 Thr 
y1 119.10 118.16
a Tyr 
y2 282.16 282.15 Ser 
y3 369.19 369.15 Asp 
y4 484.22 483.22
a Gly 
y5 573.27 573.22 Arg 
z6 680.33 680.26 Gly 
Fragment Expected Found Residue 
b1 58.09 N/A - 
b2 214.19 214.13 Gly 
b3 271.21 271.15 Asp 
b4 386.23 386.16 Ser 
b5 473.27 473.21 Tyr 
b6 636.33 636.71 Thr 
y1 119.14 119.09 Tyr 
y2 282.20 282.16 Ser 
y3 369.23 369.14 Asp 
y4 484.26 484.26
a Gly 
z5 558.30 559.17 Arg 
y6 697.38 N/A - 
Fragment Expected Found Residue 
b1 58.03 N/A - 
b2 214.13 214.12 Gly 
b3 271.15 271.15 Asp 
b4 386.18 386.16 Ser 
b5 473.21 473.19 Trp 
b6 659.29 659.24 Lys 
z1 129.10 129.10 Trp 
z2 315.18 315.19 Ser 
y3 419.23 419.22 Asp 
z4 517.24 517.24
a Gly 
y5 589.28 589.28
a Arg 
z6 746.38 N/A - 
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Fragment Expected Found Residue 
b1 58.05 58.03
a Arg 
b2 214.15 214.08 Gly 
b3 271.17 270.39 Asp 
b4 386.20 386.17 Ser 
b5 473.23 473.18 His 
b6 610.29 610.21 Leu 
y1 131.11 130.19
a Leu 
y2 268.17 268.15 His 
y3 355.20 355.20 Asp 
y4 470.26 470.01
a Gly 
y5 527.28 527.21 Arg 
y6 683.38 682.37 Gly 
 
Table 4.7  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSHL-NH2 peptide (4). 
a 
Fragments were calculated by 
complementarity.   
 
 
Table 4.8  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSVP-NH2 peptide (5). 
a 
Fragments were calculated by 
complementarity.   
Fragment Expected Found Residue 
b1 58.02 N/A - 
b2 214.12 214.13 Gly 
b3 271.14 271.16
a Asp 
b4 386.17 386.16 Ser 
b5 473.20 473.19 His 
b6 610.26 610.21 Leu 
y1 131.08 130.16
a Leu 
y2 268.14 268.18 His 
y3 355.17 355.20 Asp 
y4 470.23 470.22 Gly 
y5 527.25 527.22 Arg 
y6 683.35 N/A - 
Fragment Expected Found Residue  
b1 58.01 58.08
a Arg 
b2 214.11 214.14
a Gly 
b3 271.13 271.16 Asp 
b4 386.16 386.16 Ser 
b5 473.19 473.19 Val 
b6 572.26 572.24 Pro 
y1 115.07 115.08 Pro 
y2 214.14 214.14 Val 
y3 - amine 284.14 284.13 Asp 
y4 - amine 399.18 399.16 Gly 
y5 - amine 456.20 456.16 Arg 
y6 - amine 612.29 612.24 Gly 
Fragment Expected Found Residue  
b1 58.04 58.08
a Arg 
b2 214.14 214.13 Gly 
b3 271.17 271.16 Asp 
b4 386.19 386.16 Ser 
b5 473.22 473.17 Val 
b6 572.29 572.21 Pro 
y1 115.10 115.08 Pro 
y2 214.17 214.14
a Val 
y3 - amine 284.17 283.18
a Asp 
y4 - amine 399.21 399.15 Gly 
y5 - amine 456.23 456.17 Arg 
y6 - amine 612.32 612.77 Gly 
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Fragment Expected Found Residue  
b1 58.05 N/A - 
b2 214.15 214.12 Gly 
b3 271.17 271.19 Asp 
b4 386.20 386.16 Ser 
b5 473.23 473.18 Thr 
b6 573.27 573.23 Trp 
y1 204.10 204.12 Thr 
y2 305.15 305.14 Ser 
z3 407.19 407.14 Asp 
y4 - amine 491.19 491.19 Gly 
y5 564.23 564.28 Arg 
y6 720.33 N/A - 
 
Table 4.9  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSTW-NH2 peptide (6). 
a 
Fragments were calculated by 
complementarity.   
 
 
Table 4.10  Experimental and calculated fragmentation of untreated (left) and sorted 
(right) H-GRGDSFA-NH2 peptide (7). 
a 
Fragments were calculated by 
complementarity.   
Fragment Expected Found Residue  
b1 58.04 N/A - 
b2 214.14 214.12 Gly 
b3 271.16 271.15 Asp 
b4 386.19 386.17 Ser 
b5 473.22 473.2 Thr 
b6 573.26 573.22 Trp 
y1 204.09 204.11 Thr 
y2 305.14 305.15 Ser 
z3 407.18 407.14 Asp 
y4 - amine 491.18 491.20 Gly 
y5 564.22 564.27
a Arg 
y6 720.32 N/A - 
Fragment Expected Found Residue  
b1 58.03 58.05
a Arg 
b2 214.13 214.13 Gly 
b3 271.15 271.15 Asp 
b4 386.18 386.17 Ser 
b5 473.21 473.20 Phe 
b6 619.27 619.36 Ala 
y1 89.07 89.00
a Phe 
y2 236.14 236.12 Ser 
y3 323.17 323.16 Asp 
y4 438.20 438.16 Gly 
y5 495.22 496.24 Arg 
z6  634.29 634.27 Gly 
Fragment Expected Found Residue  
b1 58.07 N/A - 
b2 214.17 214.13 Gly 
c3  289.23 289.14 Asp 
b4 386.22 386.16 Ser 
b5 - amine 456.22 456.17 Phe 
b6 619.31 620.26 Ala 
y1 89.11 89.13
a Phe 
y2 236.18 235.12 Ser 
y3 323.21 323.14 Asp 
y4 438.24 438.28
a Gly 
y5 495.26 495.26 Arg 
y6 - amine 634.33 N/A - 
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Scheme 4.2    Possible fragmentation patterns of the Arginine side chain.  
 
Considering that cells were still bound to peptide-conjugated Tentagel beads after 
sorting, attempts were made to facilitate cell removal via sequential heating at 60 
o
C and 
95 
o
C over 10 min and 15 min, respectively. Unfortunately, this methodology prevented 
proper fragmentation of peptide sequences by MALDI-TOF/TOF to such an extent that 
no fragmentation was observed for peptides 3, 5, 6, and 7, while partial fragmentations 
were observed for other peptides. This could have been resulted from peptide 
decomposition or release from Tentagel beads. Although attempts to facilitate cell 
removal were not successful, complete sequencing of library peptides, without cell 
removal via sequential heating, proves this process to be unnecessary.  
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4.4     Conclusions  
A novel and rapid cell-based, on-bead, and fully automated screening process for 
one-bead one-compound libraries was developed. As proof of concept, a small library of 
heptameric peptides expressing the GRGDS moiety, known to bind αvβ3 integrins, was 
synthesized on Tentagel beads. The peptide-conjugated beads were screened against αvβ3 
expressing MDA-MB-435 cell-line, which were transfected with GFP protein. Cells were 
fixed to beads via formaldehyde treatment. Automated isolation of hit beads was 
accomplished using a COPAS large particle flow cytometer. MALDI-TOF/TOF analysis 
and successful sequencing of all prepared peptides indicated efficient screening and 
isolation of hit beads by the COPAS flow cytometer. An attempt was made to facilitate 
removal of cells from beads after sorting. However, this resulted in peptide 
degradation/release from Tentagel beads. This process, however, was deemed 
unnecessary since peptide sequences were deconvoluted successfully without removing 
cells from the Tentagel beads.  
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CHAPTER 5.   Outlook and Concluding Remarks 
 
The research discussed in this dissertation provides new possibilities and insights 
into the preparation of nuclear (PET/SPECT) and fluorescent (fluorescence microscopy) 
imaging probes, entailing several important findings which should be considered in the 
basic design of a tracer, especially when working with peptides or multiple imaging 
modalities. These findings include: 1) charge distribution on the peptide backbone 
contributes to probe clearance and uptake pathways, 2) by using porphyrin derivatives, a 
single molecule tracer can be developed for multimodality imaging, without requiring the 
use of multiple imaging tags or structural modifications, and 3) screening of OBOC 
libraries can be facilitated by using a fluorescent-based cell sorter, after fixing cells to 
beads, and utilized immediately after library preparation. Here, the significance of these 
findings and their contribution to the field of molecular/diagnostic imaging is discussed in 
more detail.    
The first important finding was discovered in the development of peptide-based 
tracers for beta cell imaging. Nine GLP-1 analogues were initially prepared and evaluated 
in vitro. Among these, several promising candidates were identified, the most promising 
of which was used for in vivo evaluation. Although pancreatic uptake was confirmed ex-
vivo, non-specific uptake of the tracer in kidneys prevented direct visualization of islets. 
Following these observations, the imaging probe was structurally modified in order to 
reduce kidney retention. Results obtained in this research suggested that the localization 
and clearance of peptide-based probes could be significantly altered based on the charge 
localization on the peptide backbone. This is an important observation as the non-specific 
uptake of tracers often interfere with proper in vivo evaluation of targeting agents. This 
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interference, as suggested by results in this dissertation, could be circumvented by 
perturbation of charge distribution in peptide-based agents, thereby improving images 
obtained in in vivo studies. This is especially noteworthy in the development of tracers 
targeting GLP-1R, considering the intended biological disease (diabetes), and the 
potential contribution towards the development of a cure.    
Until now, there have been no reports on an imaging probe that could be used for 
the non-invasive and direct visualization of pancreatic islets in vivo. The development of 
a probe for this application would allow not only the visualization but also the 
quantification of beta cell mass during the onset of diabetes type 1 and its progression 
into diabetes type 2. This would serve as a more efficient route of monitoring disease 
progression while, perhaps, providing the experts with a better method of analysis for 
beta cell transfer operations, thereby providing better options for the treatment of this 
illness.
1
 Visualization of beta cell mass could also prove to be a valuable diagnostic tool 
for monitoring of other disease processes involving GLP-1R receptors, such as pancreatic 
cancers (e.g. insulinomas). While the optimization process is currently ongoing, the work 
discussed in this dissertation provides potential imaging probe candidates that could be 
used for the above application.   
 The second finding concerns the basic design of multimodality imaging 
probes. In recent years, utilization of multiple imaging modalities has gained significant 
popularity since it provides more information on targeted biological entities. This move 
towards multimodality imaging requires the development of appropriate tracers for use 
with the intended instrumentation. A progression in this field was observed with the 
development of multimodality single molecule probes. However, such compounds were 
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commonly prepared by attachment of multiple imaging tags, which altered the innate 
properties of the parent molecule. This also resulted in unexpected and in consistent in 
vivo properties, in between modalities. The use of a single molecule for multimodality 
imaging, without structural modifications or addition of multiple imaging tags, is the next 
step in the development of more efficient imaging probes. A recent report by Valliant and 
coworkers provided an example of this concept.
2
 The work in this dissertation puts forth 
a new route for the development of such probes using porphyrins for both fluorescence 
and radiometal chelation. In confirming this ideology, gallium-chelated porphyrins, 
containing the integrin-targeting moiety RGD, were developed. Surprisingly, optical 
analysis of the prepared compounds indicated metal-dependent fluorescence-quenching 
to be minimal. This is contrary to reported literature on the negative impacts of metal 
chelation (Mg, Sn, Zn) on fluorescence quantum yields of PPIX.
3
 Furthermore, in vitro 
analysis proved the potential of the developed tracers for fluorescence microscopy, while 
radiolabeling experiments confirmed the potential for PET imaging. This methodology 
could prove to be particularly beneficial in bridging the gap between the screening 
processes requiring initial in vitro evaluation, by means of fluorescence microscopy, and 
in vivo detection via nuclear imaging, with implications in the development of novel 
probes, drugs and therapeutics.     
This work also provides a more efficient and facile route for screening peptide 
libraries. Although a number of screening methods have already been reported in 
literature,
4-6
 there are currently no reports on a cell-based procedure which can be used 
with OBOC peptide libraries without the need for structural modification. As a result this 
procedure simplifies the screening process by providing users with the ability to evaluate 
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novel peptide sequences, immediately after synthesis, in a time and cost-efficient fashion. 
While this method was validated with a small peptide library, its application can 
potentially be extended to also include other compounds such as small molecules or 
proteins. 
    In overview, this dissertation provides new routes for the synthesis and 
screening of peptide-based agents with applications in diagnostic imaging and potentially 
oncology. In addition, this research not only offers new insight into pharmacokinetic 
control with structural modifications, but also presents novel synthetic routes for 
preparation of more reliable and efficient multimodality imaging agents. The results 
described herein will contribute to the discovery of targeting ligands in basic sciences and 
ultimately to the discovery of new drugs and therapeutics.        
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APPENDIX I - CHAPTER 2 
HPLC and MS-ESI spectra of 1 (Purity 90%) 
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HPLC and MS-ESI spectra of 2 (Purity 98%) 
 
 
 
 
Solvent 
Peak 
196 
  
HPLC and MS-ESI spectra of 3 (Purity 95%) 
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HPLC and MS-ESI spectra of 4 (Purity 90%) 
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HPLC and MS-ESI spectra of 5 (85.3%) 
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HPLC and MS-ESI spectra of 6 (Purity 97%) 
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HPLC and MS-ESI spectra of 7 (Purity 98%) 
 
 
 
 
Solvent 
Peak 
201 
  
HPLC and MS-ESI spectra of 8 (Purity 95.3%) 
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APPENDIX II – CHAPTER 3 
UV and ESI-MS Spectra of HPLC-Purified 2 
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UV and ESI-MS Spectra of HPLC-Purified 3 
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UV and ESI-MS Spectra of HPLC-Purified 4 
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UV and ESI-MS Spectra of HPLC-Purified 5 
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UV and ESI-MS Spectra of HPLC-Purified 6 
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UV and ESI-MS Spectra of HPLC-Purified 7 
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UV and ESI-MS Spectra of HPLC-Purified 8 
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UV and ESI-MS Spectra of HPLC-Purified 9 
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APPENDIX III - CHAPTER 4 
 
 
 
 
MS/MS spectrum of untreated H-GRGDSYT-NH2 (2) post cleavage from tentagel resin 
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MS/MS spectrum of sorted H-GRGDSYT-NH2 (2) after cleavage from tentagel resin 
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MS/MS spectrum of untreated H-GRGDSWK-NH2 (3) after cleavage from tentagel resin 
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MS/MS spectrum of sorted H-GRGDSWK-NH2 (3) after cleavage from tentagel resin 
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MS/MS spectrum of untreated H-GRGDSHL-NH2 (4) after cleavage from tentagel resin 
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MS/MS spectrum of sorted H-GRGDSHL-NH2 (4) after cleavage from tentagel resin 
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MS/MS spectrum of untreated H-GRGDSVP-NH2 (5) after cleavage from tentagel resin 
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MS/MS spectrum of sorted H-GRGDSVP-NH2 (5) after cleavage from tentagel resin 
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MS/MS spectrum of untreated H-GRGDSTW-NH2 (6) after cleavage from tentagel resin 
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MS/MS spectrum of sorted H-GRGDSTW-NH2 (6) after cleavage from tentagel resin 
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MS/MS spectrum of untreated H-GRGDSFA-NH2 (7) after cleavage from tentagel resin 
 
 
 
 
 
 
 
 
 
221 
  
 
 
 
 
MS/MS spectrum of sorted H-GRGDSFA-NH2 (7) after cleavage from tentagel resin 
 
 
 
 
 
 
 
 
 
222 
  
APPENDIX IV - COPYRIGHT APPROVAL 
 
 
 
223 
  
APPENDIX V - ETHICS APPROVAL 
 
 
 
224 
  
CURRICULUM VITAE 
 
 
Name:   Babak Behnam Azad 
 
Post-secondary  The University of Western Ontario 
Education and  London, Ontario, Canada 
Degrees:   2007-2011 Ph.D. 
 
McMaster University 
Hamilton, Ontario, Canada 
2005-2007 M.Sc. 
 
McMaster University 
Hamilton, Ontario, Canada 
2000-2005 Hon. B.Sc. 
 
 
Honours and  Ontario Graduate Scholarship in Science and Technology  
Awards:   2008-2009 
 
Related Work  Teaching Assistant 
Experience:   The University of Western Ontario 
2007-2011 
McMaster University 
2003-2007 
 
Research Associate 
McMaster Hospital  
2005-2007 
 
Research Student 
McMaster University  
2003-2004 
 
Laboratory Manager  
McMaster University 
2002 
 
 
Publications: 
 
Behnam Azad, B.; Rota, V.; Breadner, D.; Dhanvantari, S. and Luyt, L. Design, 
synthesis and in vitro characterization of Glucagon-Like Peptide-1derivatives for 
pancreatic beta cell imaging by SPECT, Bioorganic and Medicinal Chemistry, 2010, 18, 
1265-1272. 
225 
  
 
Behnam Azad, B.; Ashique, R.; Schrobilgen, G. J. and Chirakal, R. “Oxygen Difluoride: 
a Highly Selective Electrophilic Fluorinating Agent for m-tyrosine”, Journal of Fluorine 
Chemistry, 2008, 129, 22-27. 
Behnam Azad, B.; Schrobilgen, G. J. and Chirakal, R., “Trifluoromethanesulfonic Acid, 
An Alternative Solvent Medium for the Direct Electrophilic Fluorination of Aromatic 
Amino Acids: New Syntheses of [
18
F]6-Fluoro-L-DOPA and [
18
F]6-Fluoro-D-DOPA”, 
Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50 (14), 1236-1242. 
 
Presentations 
Behnam Azad, B.; Cho, C-F.; Lewis, J. D. and Luyt, L. “Development of a Dual 
Modality Imaging Probe for PET and Fluorescence Imaging”, Pacifichem (Oral), Hawaii, 
Dec. 15-20, 2010. 
Behnam Azad, B.; V. Rota; S. Dhanvantari; M. Kovacs and L. Luyt, “Fluorine-18 
Labeled GLP-1 Peptides for Beta Cell Imaging”, International Society of 
Radiopharmaceutical Sciences (Poster), Edmonton, Alberta, July 23-27, 2009. 
Behnam Azad, B.; Ashique R.; and Chirakal, R. V. “Temperature Effect on the 
Stereospecificity of nucleophilic Fluorination: Formation of [
18
F]trans-4-Fluoro-L-
Proline during the synthesis of [
18
F]cis-4-Fluoro-L-Proline”, International Society of 
Radiopharmaceutical Sciences  (Poster), Edmonton, Alberta, July 23-27, 2009. 
Behnam Azad, B.; Breadner, D.; Tai; J. H.; Dhanvantari, S.; Luyt, L. “Glucagon-Like 
Peptide-1 Derivatives for SPECT Imaging of Pancreatic Islets”, World Molecular 
Imaging Congress  (Poster), Nice, France, Sept. 10-13, 2008. 
 
 
 
